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1. INTRODUCTION 
1.1 The c-MYC oncogene 
   The MYC gene family consists of several members (c-MYC, N-MYC, L-MYC, B-MYC 
and S-MYC) and was discovered by studying oncogenic retroviruses causing chicken 
tumors. MYC is named after the myelocytomatosis disease that results from infection 
with a retrovirus encoding a viral MYC (v-MYC) gene (Duesberg & Vogt, 1979; Hu et al, 
1979; Sheiness & Bishop, 1979). 
   The human c-MYC (cellular MYC) gene is located on chromosome 8q24.21 and 
contains three exons. The c-MYC protein belongs to the family of basic helix-loop-helix 
leucine zipper (bHLH-LZ) transcription factors. c-MYC dimerizes with the bHLH-LZ 
protein MYC associated factor X (MAX) via its C-terminal region (reviewed in (Dang et 
al, 1999)). The heterodimer formation is necessary for the binding to enhancer box (E-
Box) motifs CA(C/T)GTG via the basic region (Eilers & Eisenman, 2008). The N-
terminal region contains two highly conserved c-MYC homology boxes (MBI and MBII) 
which mediate cellular transformation and are responsible for transactivation (reviewed 
in (Meyer & Penn, 2008)). The c-MYC-induced transcriptional program includes 
promotion of cell cycle progression, cell growth as well as the regulation of telomerase 
activity, cell motility, metabolism and vascularization (reviewed in (Jung & Hermeking, 
2009)). The regulation of target genes occurs mainly via binding of c-MYC/MAX 
heterodimers to E-boxes and regulation of gene transcription by various mechanisms. 
Recruitment of different co-factors supports the effects on gene expression by various 
mechanisms, among them chromatin modification, chromatin remodeling, histone 
phosphorylation and promoter clearance (Cowling & Cole, 2006; Dang et al, 1999; Jung 
& Hermeking, 2009; Meyer & Penn, 2008). Repressive functions of c-MYC are, at least 
in part, mediated by a c-MYC/MAX/ MYC-interacting zinc finger protein-1 (MIZ1) (or 
SP1/NFY) complex binding to initiator region (INR) elements in the DNA and the 
replacement of co-activators or co-repressors by this multi-protein complex (Meyer & 
Penn, 2008). 
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1.1.1 c-MYC and cancer 
   In normal cells the c-MYC proto-oncogene is stringently regulated by multiple 
upstream effectors such as different signaling pathways as for example WNT (wingless-
related integration site), Hedgehog, Notch, transforming growth factor-β (TGF-β) and 
many receptor tyrosine kinases (RTKs) (Dang, 2012). In the vast majority of tumors the 
MYC family members are deregulated by various mechanisms such as translocations, 
amplifications and transcriptional deregulation by mutations in upstream regulators 
(Beroukhim et al, 2010; Eilers & Eisenman, 2008; Vervoorts et al, 2006). Enhanced 
activity of c-MYC has been observed in a variety of tumor types including hematological 
malignancies such as Burkitt’s lymphoma (91%) and solid tumors originating from the 
prostate (70%), colon (67%) and breast (45%) (Bubendorf et al, 1999; Buttyan et al, 
1987; Fleming et al, 1986; Frost et al, 2004; Naidu et al, 2002). Besides deregulation of 
cell proliferation and growth c-MYC influences additional aspects of tumor biology such 
as vascularization, metastasis, genomic instability, proteolysis and alterations in the 
tumor microenvironment (Baudino et al, 2002; Felsher & Bishop, 1999; Gavioli et al, 
2001; Pelengaris et al, 2002; Shchors et al, 2006). 
   In colorectal cancer (CRC) the loss of the adenomatous polyposis coli (APC) protein, 
which is part of the β-catenin destruction complex of the WNT pathway, is the major 
initiating event. Loss of Apc in the mouse small intestine results in constitutively active 
Wnt signaling, which is characterized by nuclear β-catenin and induction of c-MYC as a 
WNT target gene (He et al, 1998; Sansom et al, 2004). Furthermore, stabilization of the 
c-MYC protein upon Apc loss is mediated by ERK signaling (Lee et al, 2010). Moreover, 
it has been shown that phosphatase 2A (PP2A, also CIP2A), itself being over-
expressed in a number of malignancies such as e.g. colon, gastric and breast cancer, 
can stabilize the c-MYC protein during colorectal cancer progression (summarized in 
(Myant & Sansom, 2011)). The induction of c-MYC leads to an increase in reactive 
oxygen species (ROS), which is presumably caused by enhanced mitochondrial 
biogenesis and metabolic functions and has been implicated in genomic instability 
(Dang, 2012). Normal cells with normal regulated c-MYC have appropriate 
compensatory mechanisms to detoxify free oxygen radicals. However, highly activated 
c-MYC induces a sustained ROS insult on the genome, which causes genomic 
instability. Additionally, c-MYC can directly induce telomerase activity and thereby 
promote immortalization (reviewed in (Dang, 2012)). 
2
1.2 ZNF281/ZBP-99 
   The ZNF281/ZBP-99 protein has first been identified less than fifteen years ago in a 
yeast one-hybrid screen for proteins that bind to GC-rich sequences and was therefore 
first named GC-box-binding zinc-finger protein (GZP1) (Lisowsky et al, 1999). The 
ZNF281 gene is phylogenetically conserved among mammals and is located on 
chromosome 1q32.1 (Law et al, 1999). The ZNF281 protein displays characteristics of a 
transcription factor since it contains four C2H2 zinc-finger domains (residues 263 to 368) 
separated by the STGREKRPFY consensus motif typical for the Krüppel zinc finger family 
(see also Figure 1). Further features are poly-glycine, poly-proline and poly-histidine 
stretches, a basic region as well as a bipartite nuclear localization signal (Law et al, 
1999; Lisowsky et al, 1999). ZNF281 shares substantial sequence homology with the 
ubiquitously expressed ZBP-89/ZFP148 protein (28% identity and additionally 30% 
similarity), which is especially pronounced in the zinc finger domains with 79% identity 
and 91% sequence similarity (Lisowsky et al, 1999). The ZBP-89 protein has been 
implicated in the regulation of cell proliferation (Bai & Merchant, 2001), apoptosis (Bai et 
al, 2004), differentiation (Li et al, 2006) and tumorigenesis (Law et al, 2006b). Elevated 
levels of ZNF281 have been detected in placenta, kidney, brain, heart, liver and 
lymphocytes, whereas most other tissues display detectable albeit low ZNF281 
expression (Fidalgo et al, 2011; Law et al, 1999). 
   Recently, a direct interaction between ZNF281 and c-MYC has been detected (Koch 
et al, 2007). Moreover, it has been shown that ZNF281 mediates transcriptional 
repression and activation (Wang et al, 2008). For example, ZNF281 directly regulates 
the expression of gastrin and HIS3 and represses ornithine decarboxylase (ODC) by 
binding to GC-rich sequences in their promoters and activates the expression of a HIS3 
reporter gene (Law et al, 1999; Lisowsky et al, 1999). Similar to ZNF281 other 
transcription factors, such as Sp1 and Sp3, which belong to the Sp/Krüppel-like factor 
(KLF) family of transcription factors, have been shown to bind to GC-rich regions (Griffin 
et al, 2003; Nagaoka et al, 2001). Therefore, overlapping DNA-binding specificities of 
those Sp/KLF family members with ZNF281 may result in competition for binding to 
regulatory sequences and establishes a complex network of gene regulation (Black et 
al, 2001; Griffin et al, 2003). 
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Figure 1: Structural comparison between ZNF281/ZBP-99 and ZFP-148/ZBP-89. Numbers 
represent amino acids (aa). Colored boxes represent the indicated domains. Modified from 
(Hahn & Hermeking, 2014, revised version submitted) 
 
   A chromatin immunoprecipitation (ChIP) analysis in mouse embryonic stem cells 
(ESCs) ectopically expressing ZNF281 revealed more than 2,000 direct ZNF281 targets 
including several known regulators of pluripotency (Wang et al, 2008). Moreover, 
ZNF281 seems to be required for the regulation and maintenance of pluripotency by 
interacting with the core transcriptional regulatory network factors controlling the stem 
cell state such as NANOG, OCT4 and SOX2 (Wang et al, 2006; Wang et al, 2008). 
Additionally, ZNF281 directly regulates NANOG expression and contributes to its auto-
regulation by recruiting the NuRD complex in mouse ESCs (Fidalgo et al, 2012; Fidalgo 
et al, 2011). A microarray analysis revealed activated and repressed genes upon 
ZNF281 knock-down, indicating bifunctional roles of ZNF281 in the regulation of gene 
expression within different networks (Wang et al, 2008). 
   Several different knock-out and knock-down studies of ZNF281 and ZBP-89 have 
been performed in order to delineate the function of these genes (summarized in 
Table 1). The importance of ZNF281 for development was first demonstrated by Fidalgo 
et al., who showed that homozygous deletion of ZNF281 results in embryonic lethality 
between day 7.5 and 8.5 (E7.5-8.5), whereas mice with deletion of one allele showed 
no obvious phenotype (Fidalgo et al, 2011). The underlying cause of lethality has so far 
not been determined. Furthermore, loss of ZNF281 inhibited differentiation of ESCs into 
embryoid bodies (Fidalgo et al, 2011). The first studies of mice deficient for the ZNF281 
paralog ZBP-89 revealed that loss of one ZBP-89 allele blocks germ cell 
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differentiation (Takeuchi et al, 2003) and homozygous targeting of ZBP-89 exon 4 
resulted in postnatal lethality (Law et al, 2006a). In addition, treatment with dextran 
sulphate sodium (DSS) led to increased intestinal inflammation and colitis in mice with 
deletion of ZBP-89 exon 4 (Law et al, 2006a). Tissue-specific deletion of ZBP-89 in 
intestinal epithelial cells increased the susceptibility to colitis and sepsis after infection 
with Salmonella typhimurium, which was, at least in part, due to decreased secretion of 
antimicrobial peptides and reduced 5-hydroxytryptamine (5-HT) production in response 
to butyrate (Essien et al, 2013). In another study ZBP-89 deficiency caused embryonic 
lethality at around E9.5 due to anemia and neural tube defects (Woo et al, 2008). In a 
different study ZBP-89 deficiency resulted in newborn lethality at a high frequency 
(postnatal day 1 (P1) ~50%, P21 ~70%) due to respiratory distress caused by 
incomplete maturation of the prenatal lung (Sayin et al, 2013).  
   SOX4 directly induces ZNF281 transcription (Scharer et al, 2009). The SOX4 
transcription factor is critical for vertebrate development since it coordinates 
differentiation and proliferation of various tissue types. SOX4 has been implicated in the 
regulation of epithelial-mesenchymal transition (EMT) and shows increased expression 
in many human cancers besides its regulatory functions during differentiation and 
proliferation (Tiwari et al, 2013; Zhang et al, 2012b). Moreover, after DNA damage the 
ZNF281 protein is phosphorylated by ataxia telangiectasia mutated (ATM) and ATM 
and Rad3-related (ATR) kinases (Matsuoka et al, 2007) (Figure 2). Interestingly, it has 
been demonstrated that the ZNF281 paralog ZBP-89 interacts with ATM and mediates 
recruitment of ATM to GC-rich elements in the p21waf1 promoter (Bai et al, 2006). ZBP-
89 is phosphorylated at serine 202 within its zinc finger domain (Bai & Merchant, 2007), 
which is highly conserved between ZNF281 and ZBP-89 (Law et al, 1999). Therefore, 
ZNF281 is presumably also phosphorylated by the ATM kinase within its zinc finger 
domain. 
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Figure 2: Cellular functions of ZNF281. The known affectors influencing ZNF281 expression 
or effecting ZNF281 via protein binding (dotted line) or phosphorylation are indicated in dark 
blue, whereas ZNF281 regulated target genes and the effected pathways are indicated by 
green and light blue rectangles. Dashed lines indicate connections (protein interactions, gene 
regulations) for which the functional consequences still have to be determined. Modified from 
(Hahn & Hermeking, 2014, revised version submitted). 
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1.3 Epithelial-mesenchymal transition (EMT) 
   The EMT is an important mechanism, which is involved in several developmental 
processes (see below) and represents a morphological switch in the cellular phenotype. 
During EMT epithelial cells lose their differentiated characteristics including cell-cell-
adhesions as well as polarity and therefore their compactly layered organization and 
gain mesenchymal features such as decreased cell-cell contacts and loss of polarity. 
Thereby, EMT promotes increased motility and invasion. EMT not only plays important 
roles during embryonic development, but also contributes to carcinogenesis by 
promoting metastasis (Hugo et al, 2007; Lee et al, 2006; Polyak & Weinberg, 2009; 
Thiery, 2002; Thiery & Sleeman, 2006).  
   EMT is a morphogenic program that is involved in the formation of tissue and organs 
during embryonic development and wound healing. EMT has been observed in various 
tissue modeling events such as gastrulation (mesoderm formation), development of the 
prevalvular mesenchyme in the heart, formation of neural crest cells and secondary 
palates, the regression of the Müllerian duct as well as the process of somatogenesis 
(Yang & Weinberg, 2008). The key EMT programs occurring during early embryonic 
development are represented by the mesoderm formation and the development of the 
neural crest. During heart valve development and the formation of the secondary palate 
well-differentiated epithelial cells become mesenchymal cells (Yang & Weinberg, 2008). 
The latter raises the possibility that also in adult tissue EMT may appear under specific 
physiological or pathological conditions. Interestingly, the reverse program of 
mesenchymal-epithelial transition (MET) occurs during embryonic development as well 
as during carcinogenesis (Boyer & Thiery, 1993; Yang & Weinberg, 2008). 
 
1.3.1 EMT and cancer 
 
1.3.1.1 Molecular regulation of EMT 
   Several studies revealed that EMT can be regulated by numerous distinct signaling 
pathways in various organisms and different tissue culture systems. EMT is mainly 
regulated by extra-cellular signals such as for example by growth factors, tumor-stroma 
cell interactions as well as hypoxia. Furthermore, intra-cellular regulators as for example 
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transcription factors and non-coding RNAs control EMT (Figure 3) (Kalluri & Weinberg, 
2009; Polyak & Weinberg, 2009; Yang & Weinberg, 2008). 
   The multiple extra-cellular mechanisms, which can initiate an EMT, are linked to a 
complex crosstalk between down-stream signaling pathways and transcription factors, 
which often includes feed-back regulations (Peinado et al, 2007; Thiery & Sleeman, 
2006). Usually, the induction of EMT is accompanied by a core gene-expression 
signature (Peinado et al, 2007; Taube et al, 2010). So far only a few transcription 
factors such as SNAIL, SLUG, TWIST1/2 and ZEB1/2 are thought to constitute the 
central regulatory core of EMT (Peinado et al, 2007; Sanchez-Tillo et al, 2012). There 
exists an extensive crosstalk between EMT regulating pathways and EMT-inducers, 
which triggers this program commonly by down-regulating e.g. the scaffold protein and 
epithelial marker E-cadherin and further regulation of specific epithelial and 
mesenchymal genes (Thiery, 2002; Zeisberg & Neilson, 2009). The zinc-finger 
transcription factor SNAIL is one of the best studied inducers of EMT (de Herreros et al, 
2010). SNAIL directly binds to E-Box motifs (CACCTG) in the promoter region to 
repress CDH1/E-cadherin (Batlle et al, 2000; Cano et al, 2000; de Herreros et al, 2010). 
SNAIL expression correlates with the hypermethylation of the CDH-1/E-cadherin 
promoter (Takeno et al, 2004). SNAIL mainly acts as transcriptional repressor, however 
recent data also show direct induction of target genes by SNAIL (De Craene et al, 2005; 
Guaita et al, 2002; Rembold et al, 2014; Vetter et al, 2010). Moreover, SNAIL is 
expressed in invasive carcinoma cells (Batlle et al, 2000; Cano et al, 2000) and SNAIL 
expression has been associated with repression of E-cadherin, poor prognosis, tumor 
recurrence and metastasis in breast carcinomas (Peinado et al, 2007). SNAIL can be 
induced by TGF-β (Peinado et al, 2003) and forms a complex with SMAD proteins to 
bind in concert to the CDH1-promoter (Vincent et al, 2009). The ZEB (zinc finger E-box-
binding homeobox protein) family of transcription factors, consisting of ZEB1 and ZEB2, 
are also inducers of EMT and repressors of CDH-1 (Vandewalle et al, 2005). ZEB 
expression further resulted in the repression of other components of tight and adherens 
junctions as well as desmosomes (Vandewalle et al, 2005). Inhibition of ZEB by the 
microRNA-200 family (miR-200) restores the expression of E-cadherin (Gregory et al, 
2008; Park et al, 2008). ZEB expression is elevated in a variety of cancer types 
including ovarian, gastric, pancreatic and colorectal tumors (Peinado et al, 2007). 
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 Figure 3: Schematic summary of molecular mechanisms regulating EMT. During EMT 
(epithelial-mesenchymal transition) epithelial cells (pale orange, E) are converted into 
mesenchymal-like cells (green, M). The reverse transition from mesenchymal to epithelial cells 
is known as MET (mesenchymal-epithelial transition) (Hahn & Hermeking, 2014, revised version 
submitted). 
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   Members of the TGF-β family constitute some of the best characterized activators of 
EMT (Massague, 2008; Yang & Weinberg, 2008). In normal epithelial cells TGF-β can 
act growth-inhibitory, whereas in transformed cells it can promote carcinogenesis by 
induction of EMT (Shi & Massague, 2003; Siegel & Massague, 2003). Besides the 
direct TGF-β-mediated activation of the core EMT transcription factors TGF-β can 
induce EMT through multiple mechanisms since it influences cell polarity and tight 
junction formation by phosphorylating SMAD proteins and PAR6A, which leads to the 
loss of apical-basal polarity via dissolving tight junctions (Ozdamar et al, 2005; Polyak & 
Weinberg, 2009). Additionally, TGF-β signaling has been linked to the regulation of 
stem cell phenotypes in breast cancer and the maintenance of human embryonic stem 
cell pluripotency (James et al, 2005; Mani et al, 2008; Morel et al, 2008). 
   Another EMT-inducing signaling pathway, which is also linked to stemness, is the 
WNT-signaling pathway. Normally, β-catenin gets degraded upon phosphorylation by 
glycogen synthase kinase-3β (GSK3β). Inhibition of GSK3β or APC inactivation leads to 
nuclear localization and transcriptional activity of the β-catenin protein. Colorectal 
cancer cells undergoing EMT show an accumulation of β-catenin in the nucleus, which 
is reversed in metastases (reviewed in (Brabletz et al, 2005a)). Moreover, the loss of 
the scaffold protein E-cadherin, which is associated with the EMT process and therefore 
the abolishment of E-cadherin-mediated sequestration of β-catenin at the cellular 
membrane, allows the translocation of β-catenin to the nucleus. In the nucleus β-catenin 
mediates WNT-target gene activation through association with lymphoid-enhancer 
binding factor 1/ T-cell factor 4 (LEF-1/TCF4) (Orsulic et al, 1999; Sadot et al, 1998). 
   Furthermore, Notch-signaling also plays a pivotal role for EMT during embryogenesis 
as well as tumorigenesis (Timmerman et al, 2004). Activation of the Notch-pathway 
upon Jagged-1 stimulation (Noseda et al, 2004) as well as in platelet-derived growth 
factor-β (PDGF-β)-driven processes results in morphological and functional changes 
consistent with EMT. Several mechanisms lead to Notch-mediated induction of SNAIL. 
Notch-intracellular domain (NICD) recruitment to the SNAIL promoter results in direct 
up-regulation of SNAIL (Sahlgren et al, 2008). Additionally, Notch promoted hypoxia-
inducible factor-1α (HIF-1α) gets recruited to the lysyl oxidase (LOX) promoter, leading 
to increased expression of LOX and to further posttranslational stabilization of SNAIL by 
LOX (Sahlgren et al, 2008). Moreover, recent studies revealed an extensive cross-talk 
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between Notch signaling and the TGF-β-pathway, which underscores the complexity of 
EMT-driving signaling pathways (Niimi et al, 2007; Zavadil et al, 2004). 
   Receptor tyrosine kinases activation may also induce EMT during embryonic and 
pathological processes (Baum et al, 2008; Hugo et al, 2007; Thiery & Sleeman, 2006; 
Yang & Weinberg, 2008). For example, exposure to hepatocyte growth factor 
(HGF)/scatter factor activates c-Met-signaling and is sufficient to induce the EMT-like 
morphological changes of epithelial Madin-Darby canine kidney (MDCK) cells via 
activation of several down-stream pathways including Ras, MAP kinase, PI3 kinase and 
Rac/CDC42 (Birchmeier et al, 1997). The scattering of the cells can also occur after 
exposure to FGF1, EGF or HGF (Boyer et al, 1997). The discovery of the induction of a 
PDGF/PDGF-receptor autocrine loop during TGF-β-mediated EMT further linked RTK-
signaling to the regulation of EMT (Grunert et al, 2003; Jechlinger et al, 2003). 
   Hypoxia induces EMT by activation of HIF-1α, HGF, SNAIL and TWIST1 as well as by 
promoting Notch- and NFκB-signaling (Gort et al, 2008). Furthermore, it has been 
shown that low O2 levels lead to an induction of EMT by GSK-3β inhibition. The 
resulting accumulation of free β-catenin and subsequent activation of the WNT-
signaling, followed by SNAIL-induction and further repression of E-cadherin leads to a 
positive feed-back loop involving EMT-regulating transcription factors and the WNT-
pathway (Cannito et al, 2008; Jiang et al, 2011). 
 
1.3.1.2 EMT in cancer progression and the invasion-metastasis cascade 
   EMT has been tightly associated with the acquisition of metastatic and stem cell traits 
in tumor cells. Around 90% of all cancer-related deaths are caused by the metastatic 
spread of cancer cells to distant sites instead of by the growth of the primary tumor 
(Nguyen et al, 2009; Valastyan & Weinberg, 2011). During metastasis formation cells 
spread from the primary tumor to distant organs, where they have devastating effects 
(Fidler, 2003; Sleeman & Steeg, 2010). The series of distinct steps leading to the 
formation of metastases is often referred to as the “invasion-metastasis-cascade” 
(Valastyan & Weinberg, 2011). During primary tumor growth cancer cells accumulate 
genetic and epigenetic changes, which enable a specific subset of the cells to escape 
from the tumor mass and invade into surrounding tissue (Scheel & Weinberg, 2012; 
Zheng & Kang, 2013). Alterations in gene expression in the tumor microenvironment 
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may also contribute to this process (Beauchemin, 2011; Joyce & Pollard, 2009). An 
initial step in metastasis is the dissemination of some tumor cells from the solid tumor 
mass. This can occur as collective migration by a small group of cells or by the 
mechanism of mesenchymal or amoeboid migration by single cells (Friedl & Alexander, 
2011). During mesenchymal migration intercellular junctions are dissolved, polarity is 
lost and migration and invasion of single cells into the tumor surrounding stroma occurs. 
This is often achieved by the activation of the cellular program of EMT (Thiery et al, 
2009; Thompson & Williams, 2008). In patient samples it could be shown that cells in 
the invasive front of various tumor types display characteristics of EMT (Brabletz et al, 
2001; Franci et al, 2006; Thiery, 2002). Furthermore, the invasive abilities enable the 
disseminated cancer cells to enter the systemic circulation (intravasation) and thereby 
spread to secondary organs. In order to allow the metastatic growth of tumor cells in 
distant organs after exiting from the vasculature into surrounding tissues (extravasation) 
this EMT-process is reversed (Scheel & Weinberg, 2012; Zheng & Kang, 2013): cells 
undergo a mesenchymal-epithelial transition (MET), revert to the epithelial state and 
proliferate, which is necessary for the outgrowth of the micro- to a macrometastasis at 
the distant site (see Figure 4) (Thiery, 2002; Thiery et al, 2009). 
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 Figure 4: EMT and MET in the progression of carcinoma and metastases. Normal epithelial 
cells lined by the basement membrane can proliferate locally, thereby giving rise to an 
adenoma. Further epigenetic changes as well as genetic alterations lead to transformation of 
the cells, resulting in a carcinoma in situ. Additional alterations can yield to the local 
dissemination of some carcinoma cells by an epithelial-mesenchymal transition (EMT) and the 
concomitant fragmentation of the basement membrane. The cells then intravasate into lymph or 
blood vessels. At distant sites, solitary carcinoma cells extravasate and either remain solitary 
(micrometastasis) or grow out to a macrometastasis through an mesenchymal-epithelial 
transition (MET) (Thiery, 2002). 
 
   EMT occurs also at later steps of the metastasizing process, besides invasion into 
stroma as crucial initial step in the metastasis formation cascade. EMT also contributes 
to tumor stemness, evasion of the immune system, escape from senescence, 
chemoresistance as well as tumor relapse (Zheng & Kang, 2013). Cancer cells 
undergoing EMT have been shown to acquire properties of cancer stem cells (CSCs) or 
tumor-initiating cells (TICs), which are necessary for metastasis formation (Brabletz et 
al, 2005b; Mani et al, 2008). Interestingly, the ability to induce both stemness and EMT 
is shared by the EMT-transcription factors (EMT-TFs) SNAIL, TWIST and ZEB1 (Mani 
et al, 2008; Wellner et al, 2009). Therefore, EMT-TFs not only contribute to the change 
of epithelial towards mesenchymal cell characteristics, but also play a crucial role in 
seeding of cancer cells by confering them with traits of self-renewal to support the 
formation of metastases (Scheel & Weinberg, 2012). 
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1.4 microRNAs 
   microRNAs (miRNAs) are small non-coding, single-stranded RNA molecules 
consisting of ~ 22 nucleotides, which specifically repress the translation of target 
mRNAs. (Esquela-Kerscher & Slack, 2006). miRNAs regulate various processes such 
as cell growth, differentiation and apoptosis as well as tumorigenesis (Esquela-Kerscher 
& Slack, 2006). Transcription of miRNAs generally is driven by RNA polymerase II 
(RNAPol II) resulting in a precursor transcript, the so-called primary (pri-) miRNA 
(Bartel, 2004). This is further processed in the nucleus by Drosha, a RNase III enzyme, 
and Pascha (DGCR8), a protein which binds to double-stranded RNAs. The resulting 
cleaved precursor (pre-) miRNA is ~ 70-nucleotides in length and folds imperfectly into 
a stem-loop structure. The pre-miRNA is exported from the nucleus to the cytoplasm by 
Exportin-5, which is a RAN GTP-dependent transporter (Brownawell & Macara, 2002). 
In the cytoplasm another processing step occurs, by which a ~ 22 nucleotide long 
double-stranded RNA (miRNA:miRNA* duplex) arises due to enzymatic cleavage of the 
pre-miRNA hairpin by Dicer, another RNase III enzyme (Hutvagner et al, 2001). This 
duplex then gets incorporated into the multiprotein RNA-induced silencing complex 
(RISC) including the Argonaute (Ago) protein. Often, a single miRNA targets the 
expression of numerous mRNAs (reviewed in (Bartel, 2009)) and more than 60% of all 
human protein-coding genes are presumably targeted by miRNAs (Friedman et al, 
2009). The targeting of selected mRNAs by RISC-incorporated miRNAs occurs via the 
up to seven nucleotides long seed sequence of the miRNA and the complementary site 
(seed-matching sequence) in the target 3´- untranslated region (3´-UTR) and results in 
the degradation or translational repression of the target mRNA (Figure 5) (Esquela-
Kerscher & Slack, 2006; Winter et al, 2009). 
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Figure 5: The biogenesis and function of microRNAs. In the nucleus microRNA (miRNA) 
genes are generally transcribed by RNA Polymerase II (RNA Pol II) to form pri-miRNA 
transcripts. These pri-miRNA transcripts are further processed by Drosha, an RNase III 
enzyme, and its co-factor, Pasha, in order to generate the ~70-nucleotide pre-miRNA precursor 
product (The mature miRNA sequence is shown in red.). The transport of the pre-miRNA into 
the cytoplasm occurs via RAN–GTP and Exportin-5. In the cytoplasm Dicer, another RNase III 
enzyme, processes the pre-miRNA to generate a transient ~22-nucleotide miRNA:miRNA* 
duplex. This duplex becomes integrated into the miRNA-associated multiprotein RNA-induced 
silencing complex (miRISC). This complex includes the Argonaute (Ago) proteins and 
preferentially the mature single-stranded miRNA (red). The targeting of selected mRNAs by 
miRNAs occurs via a stretch of seven nucleotides (the so-called seed-sequence) (Winter et al, 
2009).  
 
 
 
16
1.4.1 The miR-34 family: members, regulation and the role in cancer 
   The miR-34 family consists of the miRNAs miR-34a/b/c, which are encoded by two 
different genes, and the miRNAs miR-449a/b/c. The miR-34a gene is located on 
chromosome 1p36. The transcript encoding for miR-34b and miR-34c is located on 
chromosome 11q23 and miR-34b/c share the same pri-miRNA (reviewed and illustrated 
in (Hermeking, 2010)). The miR-449 cluster is located on chromosome five in a highly 
conserved region within the second intron of the CDC20B gene (Lize et al, 2011).  
   The miR-34 genes are directly induced by p53 via consensus p53-binding sites in the 
proximal promoter regions of the encoding genes (Bommer et al, 2007; Chang et al, 
2007; He et al, 2007; Raver-Shapira et al, 2007; Tarasov et al, 2007). It has been 
shown that ectopic expression of miR-34 family members causes a G1 arrest, cellular 
senescence or apoptosis (Bommer et al, 2007; He et al, 2007; Tarasov et al, 2007). 
Therefore, miR-34 presumably is a mediator of tumor suppression by p53. p63, a 
relative of p53 lacking a transactivation domain, directly represses miR-34a/c to 
maintain cell cycle progression (Antonini et al, 2010; Boominathan, 2010). Moreover, 
miR-34b/c is induced by activation of the WNT-signaling or by FOXO3a (Kress et al, 
2011; Tamura et al, 2013). Up-regulation of miR-34a has been shown upon oncogene-
induced senescence mediated by the ETS family transcription factor ELK1 
(Christoffersen et al, 2010). In contrast, cytokine IL-6 activated oncogenic STAT3 
transcription factor directly represses the miR-34a gene via a conserved STAT3 binding 
site (Rokavec et al, 2014). The genetic ablation of miR-34a allowed the invasion of 
colitis-associated colon cancer by activation of an IL6R/STAT3/miR-34a feedback loop 
(Rokavec et al, 2014). Furthermore, loss of miR-34a/b/c cooperates with p53 loss in 
prostate cancer progression in mouse tumor models (Cheng et al, 2014). In addition, 
miR-34a/b/c deletion cooperates with deletion of one p53 allele in a lung cancer model 
(Okada et al, 2014). The EMT-TFs SNAIL and ZEB1 have been shown to directly 
repress miR-34 by binding to E-boxes in the miR-34 promoters (Siemens et al, 2011). 
Therefore, miR-34a/b/c genes have tumor suppressive properties, which are mediated 
by down-regulation of different tumor-promoting factors. Furthermore, it has been 
demonstrated that TGF-β signaling suppresses miR-34a expression, probably via the 
TGF-β-mediated induction of the EMT-TF SNAIL (Siemens et al, 2011; Yang et al, 
2012).  
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   Low miR-34a expression levels were detected in neuroblastoma showing a frequent 
deletion of chromosome 1p36 (Welch et al, 2007). Moreover, others observed that 
down-regulation of miR-34 in various tumor types is not solely based on inactivating 
mutations of p53, but is also caused by epigenetic changes (reviewed in (Hermeking, 
2010)). The promoters of the miR-34 genes are located within CpG islands, which are 
sites of hyper-methylation. Methylation occurs upon transfer of a methyl-group by DNA-
methyltransferases (DNMTs) from S-adenosylmethionine to the C-5 position of 
cytosine, located 5’ to a guanosine which then form a CpG dinucleotide (Iacobuzio-
Donahue, 2009). This DNA methylation directly leads to the transcriptional silencing of 
genes via affecting the chromatin status. Thereby, the binding of promoter activating 
transcription factors is inhibited and recruitment of methyl-CpG-binding proteins and 
their associated repressive chromatin remodelling activities occurs (Robertson, 2005). 
Recently, it has been shown that EMT-TFs are linked to the control of the chromatin 
configuration resulting from different histone modifications (reviewed in (Tam & 
Weinberg, 2013)). 
   Furthermore, miRNAs have emerged as major regulators of EMT (Brabletz, 2012; 
Hermeking, 2012). For example, miR-34a/b/c promote MET by directly inhibiting the 
EMT-inducing factor SNAIL (Kim et al, 2011; Siemens et al, 2011). Members of the 
miR-200 family and miR-205 achieve the same effect by targeting ZEB1/2 (Gregory et 
al, 2008; Park et al, 2008). Moreover, SNAIL directly represses miR-34a/b/c 
transcription (Siemens et al, 2011), which results in a double-negative feedback loop. 
This loop represents a bistable switch, which can be locked in the mesenchymal state 
by inactivation of miR-34 genes by CpG methylation, which is often found in cancer 
cells (Hermeking, 2012; Siemens et al, 2013). Interestingly, the genes encoding the 
miR-200 and miR-34 families are both direct p53 targets and their mediation of MET 
presumably contributes to tumor suppression by p53 (Figure 6) (Hermeking, 2012).  
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Figure 6: The functions of the p53-induced miRNAs miR-34 and miR-200 in the context of 
EMT and stemness. p53-induced miRNAs and TGF-β induced EMT-TFs form a double-
negative feed-back loop controlling EMT and MET. Modified from (Siemens et al, 2011).  
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2. AIMS OF THE STUDY 
The present study had the following aims: 
 
1. Characterization of transcription factor- and microRNA-mediated regulation of 
ZNF281 expression. 
 
2. Evaluation of ZNF281-mediated cellular functions in colorectal cancer cells and 
identification of the impact of ZNF281 knock-down  
 
3. Determination of the role of ZNF281 for c-MYC- and SNAIL-mediated functions in 
colorectal cancer cells. 
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3. MATERIALS 
3.1 Chemicals and reagents 
Chemical compound Supplier 
2-(4-Amidinophenyl)-6-indolecarbamidine-
dihydrochloride (DAPI) Carl Roth GmbH, Karlsruhe, Germany 
ammonium peroxodisulfate (APS) Carl Roth GmbH, Karlsruhe, Germany 
ampicillin Sigma-Aldrich, St.Louis, MD, USA 
BD Matrigel™ Basement Membrane Matrix BD Bioscience, Heidelberg, Germany 
christal violet Carl Roth GmbH, Karlsruhe, Germany 
complete mini protease inhibitor cocktail Roche Diagnostics GmbH, Mannheim, Germany 
dimethyl-sulfoxide (DMSO) Carl Roth GmbH, Karlsruhe, Germany 
dNTPs (deoxynucleotides triphosphate) Thermo Fisher Scientific, Inc., Waltham, MA, USA 
doxycycline hyclate Sigma-Aldrich, St.Louis, MD, USA 
ECL/HRP substrate Immobilon, Merck Millipore, Billerica, MA, USA 
ethidium bromide Carl Roth GmbH, Karlsruhe, Germany 
Fast SYBR® Green Master Mix Applied Biosystems, Foster City, CA, USA 
Fast SYBR Green Master Mix Universal RT Exiqon A/S, Vedbaek, Denmark 
FCS (Fetal calf serum) Gibco®, Life Technologies GmbH, Darmstadt, Germany 
FuGENE®6 Transfection Reagent Promega, Madison, WI, USA 
Hi-Di™ Formamide Applied Biosystems, Foster City, CA, USA 
HiPerFect Transfection Reagent Qiagen GmbH, Hilden, Germany 
Hygromycin B Invitrogen GmbH, Karlsruhe, Germany 
Immobilon-P Transfer Membrane Immobilon, Merck Millipore, Billerica, MA, USA 
LB-Agar (Lennox) Carl Roth GmbH, Karlsruhe, Germany 
LB-Medium (Luria/Miller) Carl Roth GmbH, Karlsruhe, Germany 
methyl cellulose Sigma-Aldrich, St.Louis, MD, USA 
Mitomycin C  Sigma-Aldrich, St.Louis, MD, USA 
Nonidet®P40 substitute Sigma-Aldrich, St.Louis, MD, USA 
Opti-MEM® Reduced Serum Medium Life Technologies GmbH, Darmstadt, Germany 
paraformaldehyde Merck KgaA, Darmstadt, Germany 
polyHEMA (poly(2-hydroxyethyl 
methacrylate)) Sigma-Aldrich, St.Louis, MD, USA 
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Chemical compound Supplier 
ProLong Gold antifade  Invitrogen GmbH, Karlsruhe, Germany 
propidium iodide Sigma-Aldrich, St.Louis, MD, USA 
puromycin dihydrochloride Sigma-Aldrich, St.Louis, MD, USA 
Rotiphorese gel 30 (37,5:1) Carl Roth GmbH, Karlsruhe, Germany 
sea plaque® agarose Lonza Ltd, Basel, Switzerland 
skim milk powder Fluka, Sigma-Aldrich, St.Louis, MD, USA 
sodium dodecyl sulfate (SDS) Carl Roth GmbH, Karlsruhe, Germany 
temed (tetramethylethylendiamin,1,2-bis 
(dimethylamino) –ethan) Carl Roth GmbH, Karlsruhe, Germany 
TritonX 100 Carl Roth GmbH, Karlsruhe, Germany 
Tween20 Sigma-Aldrich, St.Louis, MD, USA 
water (molecular biological grade) Gibco®, Life Technologies GmbH, Darmstadt, Germany 
 
3.2 Enzymes 
Enzyme Supplier 
DNase I (RNase-free) Sigma-Aldrich, St.Louis, MD, USA 
FIREPol® DNA Polymerase Solis BioDyne, Tartu, Estonia 
Platinum® Taq DNA polymerase Invitrogen GmbH, Karlsruhe, Germany 
proteinase K Sigma-Aldrich, St.Louis, MD, USA 
restriction endonucleases New England Biolabs GmbH, Frankfurt, Germany 
RNase A Sigma-Aldrich, St.Louis, MD, USA 
T4 DNA ligase Thermo Fisher Scientific, Inc., Waltham, MA, USA 
trypsin (10x, phenol-red free) Invitrogen GmbH, Karlsruhe, Germany 
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3.3 Kits 
Kit Supplier 
BCA Protein Assay Kit  Pierce, Thermo Fisher Scientific, Inc., Waltham, MA, USA 
BigDye® Terminator v3.1 Cycle 
Sequencing Kit  Life Technologies GmbH, Darmstadt, Germany 
Dneasy® Blood&Tissue Kit QIAGEN GmbH, Hilden, Germany 
DyeEx® 2.0 Spin Kit QIAGEN GmbH, Hilden, Germany 
High Pure RNA Isolation Kit Roche Diagnostics GmbH, Mannheim, Germany 
miRCURY LNATM Universal RT microRNA 
PCR – Universal cDNA Synthesis Kit II Exiqon A/S, Vedbaek, Denmark 
Pure Yield™ Plasmid Midiprep System Promega GmbH, Mannheim, Germany 
QIAprep Spin Miniprep Kit QIAGEN GmbH, Hilden, Germany 
QIAquick Gel Extraction Kit QIAGEN GmbH, Hilden, Germany 
QuikChange II Site-Directed Mutagenesis 
Kit 
Stratagene, Agilent Technologies GmbH & Co.KG, 
Waldbronn, Germany 
Verso cDNA Kit Thermo Fisher Scientific, Inc., Waltham, MA, USA 
 
3.4 Antibodies 
 
3.4.1 Primary antibodies 
Epitope Clone Ordering no. Company Use Dilution Source 
α-tubulin DM 1A # T-9026 Sigma WB 1:1000 mouse 
β-actin   # A2066 Sigma WB 1:1000 rabbit 
β-catenin   # 610154 BD PharMingen WB 1:1000 mouse 
β-catenin   # 1247-1 Epitomics IF 1:200 rabbit 
E-cadherin  4A2C7 # 334000 Invitrogen WB; IF 1:1000; 1:50 mouse 
goat IgG  # AB-108-C R&D Systems ChIP  goat 
rabbit IgG  # R-5506 Sigma ChIP  rabbit 
SNAIL   # 3879S Cell Signaling WB; IF 1:200; 1:100 rabbit 
SNAIL  # AF3639 R&D Systems ChIP  goat 
Vimentin EPA3776 # 2707-1 Epitomics WB; IF 1:5000; 1:50 rabbit 
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Epitope Clone Ordering no. Company Use Dilution Source 
VSV   # V4888 Sigma WB; ChIP 1:7500 rabbit 
ZNF281       WB; ChIP 1:1000 rabbit 
 WB = Western blot, IF = immunofluorescence, ChIP = chromatin immunoprecipitation  
 
3.4.2 Secondary antibodies 
Name Source Application Supplier 
anti-mouse HRP goat WB Promega GmbH, Mannheim, Germany 
anti-mouse-
Alexa Fluor-555 goat IF 
Invitrogen GmbH, Karlsruhe, 
Germany 
anti-rabbit HRP goat WB Sigma-Aldrich, St.Louis, MD, USA 
anti-rabbit-Cy3 donkey IF 
Jackson Immuno-Research 
Europe Ltd., Newmarket, Suffolk, 
UK 
Phalloidin-Alexa-
647  IF 
Invitrogen GmbH, Karlsruhe, 
Germany 
 WB = Western blot, IF = immunofluorescence 
 
3.5 Vectors and oligonucleotides 
 
3.5.1 Vectors 
Name ORF/Rep Reference 
pRTR   (Jackstadt et al, 2013) 
pRTR-p53-VSV p53 (Siemens et al, 2011) 
pRTR-pri-miR-34a miR-34a (Kaller et al, 2011) 
pRTR-SNAIL-VSV SNAIL (Siemens et al, 2011) 
pRTR-ZNF281-VSV ZNF281 this work 
pRTR-c-MYC-VSV c-MYC (Jackstadt et al, 2013) 
pUC19SfiI  kind gift from Andreja 
Vasiljev 
pBV  (He et al, 1999) 
pBV-ZNF281 wt 2 kb human ZNF281 wild-type 
promoter 
this work 
pBV-ZNF281 SBS2 mut  human ZNF281 promoter mutated 
SBS2 
this work 
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Name ORF/Rep Reference 
pBV-ZNF281 SBS3 mut human ZNF281 promoter mutated 
SBS3 
this work 
pBV-ZNF281 SBS2+3 mut human ZNF281 promoter mutated 
SBS2+3 
this work 
pXP2-E-cadherin/CDH1  E-cadherin (Yang et al, 2010) 
pXP2-E-cadherin/CDH1 E-cadherin SBSs mutated (Yang et al, 2010) 
pGL3-control-MCS   (Kaller et al, 2011; Welch et 
al, 2007) 
pGL3-ZNF281wt_77bp human ZNF281 wild-type 3´UTR this work 
pGL3-ZNF281wt_fl human ZNF281 wild-type 3´UTR this work 
pGL3-ZNF281mut_77bp human ZNF281 mutated 3´UTR this work 
pGL3-TPD52 human TPD52 3´UTR (Kaller et al, 2011) 
pGL3-SNAIL promoter  
-1158/+92 
human SNAIL promoter (Barbera et al, 2004) 
pGL3-SNAIL promoter -869/+59 human SNAIL promoter (Barbera et al, 2004) 
pGL3-SNAIL promoter -514/+59 human SNAIL promoter (Barbera et al, 2004) 
pGL3-SNAIL promoter -194/+59 human SNAIL promoter (Barbera et al, 2004) 
pGL3-SNAIL promoter -78/+59 human SNAIL promoter (Barbera et al, 2004) 
RL Renilla (Pillai et al, 2005) 
pcDNA3-SNAIL-VSV SNAIL kind gift from Markus Kaller 
pcDNA3-ZNF281-VSV ZNF281 kind gift from Ru Zhang 
pRTS   (Bornkamm et al, 2005) 
pRTS-non-spec.-miRNA non specific microRNA kind gift from Ru Zhang 
pRTS-ZNF281-spec.-miRNA #1 ZNF281-specific microRNA #1 kind gift from Ru Zhang 
pRTS-ZNF281-spec.-miRNA #2 ZNF281-specific microRNA #2 kind gift from Ru Zhang 
pRTS-ZNF281-VSV ZNF281 kind gift from Ru Zhang 
pRTS-pri-miR-34a miR-34a (Tarasov et al, 2007) 
pBabe  (Morgenstern & Land, 1990) 
pBabe-SNAIL-VSV SNAIL (Siemens et al, 2011) 
pcDNA3-Luc2-tdTomato Luc2-tdTomato (Patel et al, 2010) 
pLXSN-Luc2-tdTomato Luc2-tdTomato kind gift from Rene 
Jackstadt 
 ORF = open reading frame, wt = wild-type, mut = mutant, SBS = SNAIL binding site, MCS = multiple 
cloning site, fl = full-length 
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3.5.2 Oligonucleotides 
 
3.5.2.1 Oligonucleotides used for qChIP 
Name Sequence (5’ to 3’) 
ZNF281 SBS1 fwd AGGCTGGTCTTGAACTCCTG 
ZNF281 SBS1 rev GGAAACAATCCCAGAACAAAG 
ZNF281 SBS2+3 fwd GTACCACTAATTGCGGTTTCAA 
ZNF281 SBS2+3 rev TAATGGGCGCATATCCTTTG 
ZNF281 SBS4 fwd TGTAGTGCTGCTTTCCGAAG 
ZNF281 SBS4 rev ATGCTGCACTGATCACATCC 
ZNF281 SBS5 fwd AGGACACATGGTCTCCCAAC 
ZNF281 SBS5 rev AAATCCACTCGTGGTTCTGC 
SNAIL A fwd CCCTATGGAGCCGTGTTACAG 
SNAIL A rev GAGTTTCGTTGAAAAAGATCCCTG 
SNAIL B fwd AACGGGTGCTCTTGGCTA 
SNAIL B rev GAAGCGAGGAAAGGGACAC 
SNAIL C fwd GGAGTACTTAAGGGAGTTGGCGG 
SNAIL C rev GAACCACTCGCTAGGCCGT 
SNAIL D fwd GACTCAGATTGGGTGACCTGG 
SNAIL D rev ACTCAATCAACAAACATGAGCCC 
CDH-1 TSS fwd TGAACCCTCAGCCAATCAG 
CDH-1 TSS rev AGTTCCGACGCCACTGAG 
CDH-1 -10kb fwd GCCTGGGACTGAAAGTCTTG 
CDH-1 -10kb rev CAGGGTTCTCCCAAGAACAG 
OCLN TSS fwd CGAGTTTCAGGTGAATTGGTC 
OCLN TSS rev CGGGAGTGTAGGTGTGGTGT 
OCLN -5kb fwd TCCCAAAGTGCTGGGATTAC 
OCLN -5kb rev GGCTCACTGCAGCCTCTATC 
CLDN-7 TSS fwd TTTGAGAGGGCAAAACAAAG 
CLDN-7 TSS rev CAGTTTCCTCCCAATCTTCC 
CLDN-7 -3kb fwd TGAAAGCAAAGTACTGGTAGCC 
CLDN-7 -3kb rev CCACCCACCTTCCTCTATCC 
Axin2 fwd CCAACTCACTCAGGGGAGAC 
Axin2 rev GATTCTTGGCACAGGCAGTAG 
LGR5 fwd TCTCCCAGGTCTGGTGTGTT  
LGR5 rev CACCCTGAGCAACATCCTG 
CD133 fwd AACCCAAACAAAGCAAAACC 
CD133 rev TTTGCACAGAAGCAGAAAGC 
Chr. 16q22 fwd CTACTCACTTATCCATCCAGGCTAC 
Chr. 16q22 rev ATTTCACACACTCAGACATCACAG 
              fwd = forward, rev = reverse, SBS = SNAIL binding site, TSS = transcription start site 
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3.5.2.2 Oligonucleotides used for qPCR 
Designation Sequence (5’ to 3’) 
β-actin fwd TGACATTAAGGAGAAGCTGTGCTAC 
β-actin rev GAGTTGAAGGTAGTTTCGTGGATG 
ZNF281 fwd TCTTCACCTCTCCACAACCAC 
ZNF281 rev TGTAGCATCCAAAGCAGACAA 
pri-miR-34a fwd CGTCACCTCTTAGGCTTGGA 
pri-miR-34a rev CATTGGTGTCGTTGTGCTCT 
SNAIL fwd GCACATCCGAAGCCACAC 
SNAIL rev GGAGAAGGTCCGAGCACA 
CDH-1 fwd CCCGGGACAACGTTTATTAC 
CDH-1 rev GCTGGCTCAAGTCAAAGTCC 
VIM fwd TACAGGAAGCTGCTGGAAGG 
VIM rev ACCAGAGGGAGTGAATCCAG 
SLUG fwd TGGTTGCTTCAAGGACACAT 
SLUG rev GTTGCAGTGAGGGCAAGAA 
ZEB1 fwd TCAAAAGGAAGTCAATGGACAA 
ZEB1 rev GTGCAGGAGGGACCTCTTTA 
FN-1 fwd CTTTGGTGCAGCACAACTTC 
FN-1 rev TCCTCCTCGAGTCTGAACCA 
OCLN fwd GGCCTCTTGAAAGTCCACCT 
OCLN rev CTGAGAGAGCATTGGTCGAA 
CLDN-7 fwd AGTTGCTGGGCTTCTCCAT 
CLDN-7 rev TTGGAAGAGTTGGACTTAGGG 
CDH-3 fwd ATGACGTGGCACCAACCAT 
CDH-3 rev GTTAGCCGCCTTCAGGTTCTC 
ZO-3 fwd CGTCGCCTCTACGCACAAG 
ZO-3 rev TGAAGAGGTGGCTGCTGTGTT 
PKP-2 fwd CGGAAATCTTCACCGAACCA 
PKP-2 rev AACGGCCTCCAACAAAATCAT 
DSP fwd CAGTGGTGTCAGCGATGATGT 
DSP rev TGACGCTGGATATGGTGGAA 
CLDN-1 fwd GCCCCAGTGGATTTACT 
CLDN-1 rev GTTTTGGATAGGGCCTTGGT 
TSPAN-31 fwd CGCTCTCAACGTGGTCTACA 
TSPAN-31 rev ACTCCCACAGCAATGACTCC 
ZO-1 fwd CAGGAAATCTATTTCAAGGTCTGC 
ZO-1 rev CATCACCAAAGGACTCAGCA 
β-catenin fwd AGCTGACCAGCTCTCTCTTCA 
β-catenin rev CCAATATCAAGTCCAAGATCAGC 
LGR5 fwd GCATTTGGAGTGTGTGAGAA 
LGR5 rev AGGGCTTTCAGGTCTTCCTC  
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Designation Sequence (5’ to 3’) 
CD133 fwd TCCACAGAAATTACCTACATTGG 
CD133 rev CAGCAGAGAGCAGATGACCA 
Axin2 fwd CCACACCCTTCTCCAATCC 
Axin2 rev TGCCAGTTTCTTTGGCTCTT 
GAPDH fwd GCTCTCTGCTCCTCCTGTTC 
GAPDH rev ACGACCAAATCCGTTGACTC 
             fwd = forward, rev = reverse 
 
3.5.2.3 Oligonucleotides used for cloning and mutagenesis 
Name Sequence (5’ to 3’) 
human 
ZNF281_77bp_UTR 
fwd 
GTGGCCAGGCTGGAGGTCTTCTAATGTAATTTTGTTTTATTTTGAG 
human ZNF281 
wt_77bp_UTR rev 
GGATCGTGTAGAAACATTCCAATGGCAGTGTTCTCAAAATAAAACA 
AAA 
human ZNF281 
mut_77bp_UTR rev 
GGATCGTGTAGAAACATTCCAATCCGACTGTTCTCAAAATAAAACA 
AAA 
human ZNF281 
wt_fl_UTR fwd TTTACCGGTGGTCCCAAAAGTGGCCAG 
human ZNF281 
wt_fl_UTR rev TTTCTGCAGGCGTTTAAAACATTTGGGC 
human ZNF281 
promoter fwd NheI TTTGCTAGCCCCCTTCCTTGGGCTTGA 
human ZNF281 
promoter rev EcoRI TTTGAATTCGCCTCCCGTGTACTGCG 
SBS2 mut fwd GCGTGTTTTACAGGACTGCTGACTCCTGATTACGCTCGGTTTCCT CTTC 
SBS2 mut rev GAAGAGGAAACCGAGCGTAATCAGGAGTCAGCAGTCCTGTAAAACACG 
SBS3 mut fwd GCTTCCAAATTCAAAGGGATAACATAAGACTCCTTTTTAATAAATGTTGAGCAATTTGGAG 
SBS3 mut rev CTCCAAATTGCTCAACATTTATTAAAAAGGAGTCTTATGTTATCCCTTTGAATTTGGAAGC 
fwd = forward, rev = reverse, wt = wild-type, mut = mutant, SBS = SNAIL binding site, fl = full-length 
 
3.5.3 microRNA mimics and antagomiRs 
The following pre-microRNA mimics and antagomiRs were purchased from Ambion: 
• pre-miR-control 
• pre-miR-34a 
• anti-miR-control 
• anti-miR-34a 
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3.6 Buffers and solutions 
2x Laemmli buffer: 
 125 mM TrisHCl (pH 6.8) 
 4% SDS 
 20% glycerol 
 0.05% bromophenol blue (in H2O)  
 10% β-mercaptoethanol (added right before use) 
 
Propidium iodide staining solution: 
 800 µl propidium iodide (1.5 mg/ml) 
 1000 µl RNase A (10 mg/ml) 
 ad 20 ml PBS 0.1% TritonX 100 
 
10x ‘Vogelstein‘ PCR buffer: 
 166 mM NH4SO4     
 670 mM Tris (pH 8.8)     
 67 mM MgCl2     
 100 mM β-mercaptoethanol   
 
RIPA buffer (for protein lysates): 
 1% NP40 
 0.5% sodium deoxycholate 
 0.1% SDS 
 250 mM NaCl  
 50 mM TrisHCl (pH 8.0)  
 
SDS buffer: 
 50 mM Tris (pH 8.1)  
 100 mM NaCl  
 0.5% SDS  
 5 mM EDTA  
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10x Tris-glycine-SDS running buffer (5l, for SDS-PAGE): 
 720 g Glycin  
 150 g Tris base  
 50 g SDS  
 pH 8.3-8.7 
 ad 5 l ddH2O 
 
Triton dilution buffer: 
 100 mM Tris-HCl (pH 8.6)  
 100 mM NaCl 
 5 mM EDTA (pH 8.2) 
 0.2% NaN3 
 5% TritonX-100 
 
Towbin buffer (for Western blotting): 
 200 mM glycine 
 20% methanol 
 25 mM Tris base (pH 8.6) 
 
10x TBS-T (5l): 
 500 ml 1M Tris (pH 8.0)  
 438.3 g NaCl 
 50 ml Tween20  
 ad 5 l ddH2O 
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3.7 Laboratory equipment 
Device Supplier 
5417C table-top centrifuge Eppendorf AG, Hamburg, Germany 
ABI 3130 genetic analyzer capillary 
sequencer Applied Biosystems, Foster City, USA 
Axiovert 25 microscope Carl Zeiss GmbH, Oberkochen, Germany 
BD AccuriTM C6 Flow Cytometer 
Instrument Accuri, Erembodegem, Belgium 
Biofuge fresco Heraeus; Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Biofuge pico table top centrifuge Heraeus; Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Boyden chamber transwell membranes 
(pore size 8.0 µm) Corning Inc., Corning, NY, USA 
Cflow® software Accuri, Erembodegem, Belgium 
CF40 Imager Kodak, Rochester, New York, USA 
Falcons, dishes and cell culture materials Schubert & Weiss OMNILAB GmbH & Co. KG 
Fisherbrand FT-20E/365 transilluminator Fisher Scientific GmbH, Schwerte, Germany 
Forma scientific CO2 water jacketed 
incubator 
Thermo Fisher Scientific, Inc., Waltham, MA, 
USA 
GeneAmp® PCR System 9700 Applied Biosystems, Foster City, USA 
Herasafe KS class II safety cabinet Thermo Fisher Scientific, Inc., Waltham, MA, USA 
HTU SONI130 G. Heinemann Ultraschall- und Labortechnik, Schwäbisch Gmünd, Germany 
KAPPA ImageBase software KAPPA opto-electronics GmbH, Gleichen, Germany 
Megafuge 1.0R Heraeus; Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Mini-PROTEAN®-electrophoresis system Bio-Rad, München, Germany 
MultiImage Light Cabinet Alpha Innotech, Johannesburg, South Africa 
ND 1000 NanoDrop Spectrophotometer NanoDrop products, Wilmington, DE, USA 
Neubauer counting chamber Carl Roth GmbH & Co, Karlsruhe, Germany 
Orion II luminometer Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany 
PerfectBlue™ SEDEC ‘Semi-Dry’ blotting 
system 
PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
real-time cell analyzer (RTCA) xCELLigence RTCA SP; Roche Diagnostics GmbH, Penzberg, Germany 
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Device Supplier 
Varioskan Flash Multimode Reader Thermo Scientific, Inc., Waltham, MA, USA 
waterbath Memmert GmbH, Schwabach, Germany 
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4. METHODS 
4.1 Bacterial cell culture 
 
4.1.1 Propagation and seeding 
   For replication of plasmids carrying an ampicillin resistance the E.coli XL1-blue strain 
was used. The bacterial cells were cultured in lysogeny both (LB) -medium by agitation 
(225 rpm) or on LB agar plates to obtain single cell clones. Each LB was supplemented 
with 100 μg/ml ampicillin for selection at 37°C overnight.  
 
4.1.2 Transformation 
   For transformation competent E.coli XL1-blue were used. The plasmid DNA was 
added to the bacterial cells and incubated on ice for 30 minutes. The cells were 
subjected to a heat-shock at 42°C for 45 seconds and replaced on ice for additional 
two minutes. To increase the transformation efficiency the transformed cells where pre-
incubated at 37°C for one hour. Next, the cells were plated on LB-agar plates containing 
ampicillin and cultivated at 37°C overnight. For further propagation of the plasmid a 
transformed single cell clone was used to inoculate the respective amount of LB-
medium containing the antibiotics, incubated at 37°C overnight and subjected to the 
procedure of choice to purify the plasmid DNA. 
 
4.1.3 Purification of plasmid DNA from E.coli 
   For the preparation of smaller amounts of plasmid DNA 5 ml of LB-medium 
supplemented with ampicillin were inoculated with the respective single clone of the 
transformed bacterial cells. The plasmid DNA was isolated according to the 
manufacturer’s instructions of the QIAprep Spin Miniprep Kit (Qiagen). This method was 
preferentially used due to the better yields and quality of the DNA leading to better 
transfection efficiencies. 
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Binding to a region on chromosome 16q22 served as negative control in all ChIP 
assays performed. The sequences of oligonucleotides used as qChIP primers are listed 
in chapter 3.5.2.1. 
 
4.3 Cell culture of human cells 
 
4.3.1 Propagation of human cell lines 
   The cell lines HCT-15, HEK293T, HT29, MiaPaCa2, SKBR3, SW480 and SW620, as 
well as human diploid fibroblasts (HDFs) were kept in high glucose Dulbecco`s modified 
Eagles medium (DMEM, Invitrogen). DLD-1, HCT116 p53 -/- and HCT116 p53 +/+ cells 
were cultured in McCoys medium (Invitrogen) and Colo320 in RPMI medium 
(Invitrogen). Media were supplemented with 10% fetal calf serum (FCS, Invitrogen) and 
1% Penicillin/Streptavidin (Invitrogen). For HEK293T cells 5% FCS was used. All cells 
were kept at 5% CO2 and 37°C in a humidified incubator. The same culturing conditions 
were used for the respective derivatives of the cell lines. In order to avoid any 
confluency of the cells, they were passaged every two to four days and seeded into 
fresh culturing flasks. 
 
4.3.2 Transfection of oligonucleotides and vector constructs 
   Transfections of oligonucleotides and vector constructs were carried out using freshly 
trypsinized and re-seeded (not yet settled) cells in the medium and cell culturing format 
of choice, preferentially into a six- or twelve-well format. In general the transfection 
reagent mix contained 100 µl Opti-MEM (Invitrogen), 10 µl HiPerFect (Qiagen) and 
10 µl of the respective oligonucleotide [10 µM] (Ambion – Applied Biosystems, final 
concentration [100 nM]). In order to transfect plasmid DNA the transfection mix 
consisted of 150 µl Opti-MEM, X µg DNA (as indicated in the figure legend) and 5 µl 
FuGENE6 (Promega). The mix was incubated at RT for 15-20 minutes and afterwards 
added drop-wise to the cells. After the indicated incubation time the respective assays 
were carried out. Selection of plasmid containing cells was started 48 hours after the 
transfection procedure using the appropriate antibiotics.  
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4.3.3 Conditional expression in cell pools 
   Polyclonal cell pools for conditional expression were generated by transfection of the 
episomal expression vector pRTR (Jackstadt et al, 2013) using Fugene6 (Roche) and 
selection in 2 µg/ml Puromycin (Sigma; stock solution: 2 mg/ml in water) for 10 days. 
The percentage of eGFP-positive cells was determined 48 hours after addition of 
Doxycycline (DOX) at a final concentration of 100 ng/ml (Sigma; stock solution 
100 µg/ml in water). Polyclonal cell pools transfected with the pRTS vector (Bornkamm 
et al, 2005) were similarly generated and selection occurred in 150 µg/ml Hygromycin B 
(Sigma; stock solution: 50 mg/ml) for up to 14 days. The percentage of mRFP-positive 
cells was determined 48 hours after addition of DOX at a final concentration of 1 µg/ml.  
 
4.3.4 Cryo-preservation of mammalian cells 
   Sub-confluent cells in the exponential growth phase were used for cryo-preservation 
by trypsination, resuspended with medium and pelleted by centrifugation at 1200 rpm 
for five minutes. Resuspension of the cells was done in 50% FCS, 40% growth medium 
and 10% (v/v) DMSO (Roth). Aliquots in cryo-vials were cooled down in a freezing 
device at -80°C overnight and transferred into liquid nitrogen for long term storage.  
In order to recover cells they were rapidly thawed in a water bath at 37°C, resuspended 
in medium and pelleted by centrifugation as described above. Thereafter, the cells were 
resuspended in the respective growth medium and plated in the desired format of a cell 
culture flask for further cultivation. 
 
4.3.5 Isolation of genomic DNA from human diploid fibroblasts (HDFS) 
   Genomic DNA from HDFs was generated by seeding the cells on a 10 cm2 dish at a 
conflueny of 90% at the maximum. The DNA was isolated according to manufacturer’s 
instructions using the Blood & Tissue Kit (Qiagen), eluted into a final volume of 50 µl 
and the resulting DNA content was analyzed using the Nanodrop spectrophotometer.  
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4.4 Determination of proliferation 
 
4.4.1 Determination of proliferation by cell counting 
   The proliferation of DLD-1/pRTR-ZNF281-VSV and SW480/pRTS-miR cells was 
determined by seeding 1 x 105 cells/6-well in triplicates for the indicated time-points. 
Furthermore, the cells were treated with DOX (DLD-1: 100 ng/ml; SW480: 1 µg/ml) for 
24 to 72 hours or left untreated as control. One day after seeding the 0 hours time-point 
was harvested by trypsinizing the cells and resuspending them in a defined volume of 
DMEM supplemented with 10% FCS to stop the reaction. Cell counting was done using 
the Neubauer chamber and calculation of the total cell number per well was carried out. 
The cells corresponding to the indicated time-points were harvested as described 
above. Total cell numbers are graphically shown. 
 
4.4.2 Determination of proliferation by impedance measurement 
   The optimal cell concentration was determined by serial dilution for each cell line. 
1 x 104 SW620 cells were seeded per well (96-well). Subsequently, 100 µl of cell culture 
media at room temperature was added into each well of an E-plate 16 (Roche). Proper 
electrical-contact was checked and background impedance was measured. 100 µl cell 
suspension was added to the medium-containing wells on the E-plate 16. After 
30 minutes incubation at room temperature, the E-plate 16 was placed in the 
xCELLigence device (Roche) in a cell culture incubator. Impedance was monitored 
every 60 minutes for a period of up to 110 hours. The electrical impedance is 
represented as a dimension-less parameter termed cell-index (CI). All calculations were 
performed using the RTCA software provided with the xCELLigence system. The unit-
less parameter CI represents the relative change in electrical impedance that occurs in 
the presence and absence of cells in the wells, which is calculated based on the 
following formula: CI = (Zi –Z0)/15, where Zi is the impedance at an individual point of 
time during the experiment and Z0 is the impedance at the start of the experiment. 
Impedance is measured at three different frequencies (10, 25 or 50 kHz) and a specific 
time (ref: Roche Diagnostics GmbH. Introduction of the RTCA DP Instrument. RTCA DP 
Instrument Operator‘s Manual, A. Acea Biosciences, Inc.; 2008.).  
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4.5 Episomal vectors for ectopic expression of proteins and miRNAs 
   The generation of the pRTR vector, which is an improved version of the pRTS vector 
is described in (Jackstadt et al, 2013). The VSV-tagged ZNF281 expression construct 
was generated using standard PCR and cloning techniques with pCMV-sport1-ZNF281 
(kindly provided by Juanita Merchant (Law et al, 1999)) as a template and insertion into 
the pRTS vector by using the pUC19SfiI shuttle vector and SfiI restriction sites. The 
VSV-tagged sequence of ZNF281 was excised from pRTS-ZNF281-VSV and ligated 
into the pRTR vector via the SfiI-sites. The insert orientation was verified by 
sequencing. More detailed information on the generation of the pRTR-SNAIL-VSV, the 
pRTR-p53-VSV or the pRTR-pri-miR-34a vectors are provided in (Kaller et al, 2011; 
Siemens et al, 2011). Expression plasmids used are listed in chapter 3.5.1. 
 
4.6 Flow cytometry 
 
4.6.1 Analysis of the transfection efficiency (eGFP/mRFP) 
   In order to control the transfection efficiency of the pRTR and pRTS vectors into 
mammalian cells, both vectors harbor an eGFP or mRFP gene, respectively. The 
percentage of eGFP/mRFP-positive cells was determined 48 hours without or following 
addition of DOX [100 ng/ml]. A BD AccuriTM C6 Flow Cytometer instrument (Accuri) and 
the corresponding Cflow® software served to read out the proportion of fluorescent 
cells. 
 
4.6.2 Cell cycle analysis by propidium iodide staining 
   The respective cells were cultured under the indicated conditions and treated with 
DOX or left untreated as described in the respective figure legends and depicted in the 
figure. Cells were harvested by trypsination, resuspended in DMEM or McCoys medium 
supplemented with 10% FCS respectively. Following centrifugation and removal of the 
supernatant the cells were resuspended and ice-cold ethanol (70%) was added drop-
wise. After overnight incubation at -20°C, cells were centrifuged and resuspended in 
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propidium iodide (PI) staining buffer (PBS supplemented with 0.1% TritonX 100, 1.2 mg 
propidium iodide and 10mg RNaseA) and incubated at 37°C for 30 minutes. The 
distribution of the cells according to the different cell cycle stages was determined by 
analyzing 1 x 104 cells per measurement with the BD AccuriTM C6 Flow Cytometer 
Instrument (Accuri) and the corresponding Cflow® software. Experiments were carried 
out in triplicates. 
 
4.7 Generation of Luc2 expressing SW620 cells 
   To generate the luciferase expressing vector pLXSN-Luc2-tdTomato, the Luc2 and 
tdTomato ORFs were excised from the pcDNA3-Luc2-tdTomato vector (Addgene 
Plasmid # 32904, kindly provided by Christopher Contag (Patel et al, 2010)) by using 
EcoRI sites and cloned into the pLXSN retroviral vector. For retroviral infection of 
SW620 cells, Phoenix-A packaging cells were transfected with the pLXSN-Luc2-
dtTomato vector using calcium phosphate precipitation. Retrovirus-containing 
supernatants were harvested 24 hours after transfection, passed through 0.45 µm filters 
(Millipore) and used to infect SW620 in the presence of polybrene (8 µg/ml) four times 
in four hours intervals. Selection was started 48 hours later by addition of 500 µg/ml 
geneticin (Gibco) for 14 days and subsequently a single cell clone was picked. 
 
4.8 Immunofluorescence and confocal-laser scanning microscopy 
   For immunofluorescence analysis, cells cultivated on glass cover-slides were fixed in 
4% paraformaldehyde/PBS for 10 minutes, permeabilized with 0.2% TritonX 100 for 
20 minutes and blocked in 100% FBS for 30 minutes. Primary and secondary 
antibodies are listed in chapter 3.4. F-Actin was detected with Phalloidin conjugated 
with Alexa Flour 647 (Invitrogen). Chromatin was stained by DAPI (Roth). Finally, slides 
were covered with ProLong® Gold antifade (Invitrogen).  
Laser scanning microscopy (LSM) images were captured with a confocal microscope 
(LSM 700, Zeiss) using a Plan Apochromat 20x/0.8 M27 objective, ZEN 2009 software 
(Zeiss) and the following settings were used: image size 2048x2048 and 16 bit, 
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pixel/dwell of 25.2 µs, pixel size 0.31 µm, laser power 2% and master gain 600-1000. 
After image capturing the original LSM files were converted into TIFF files. 
 
4.9 In vivo lung metastasis assay 
   72 hours after siRNA transfection 4 x 106 SW620-Luc2 cells were resuspended in 
PBS in a total volume of 0.2 ml and injected into the lateral tail vein of a six- to eight-
week-old male nonobese diabetic/severe combined immunodeficient (NOD/SCID) 
mouse using a 25-gauge needle. For monitoring of the injected cells mice were injected 
intraperitoneal with d-luciferin (150 mg/kg) and were imaged under anaesthesia with the 
IVIS Illumina System (Caliper Life Sciences) 30 minutes after tail vein injection in order 
to have a reference point. The acquisition time was set to two minutes and imaging was 
repeated once a week to monitor the seeding and outgrowth of the cells. After nine 
weeks complete lungs were resected and photographed. For hematoxylin and eosin 
(H&E) staining, lungs were fixed with 4% paraformaldehyde and 5 µm paraffin sections 
were stained with H&E. The number of metastases was determined microscopically. 
Mice were kept under IVC conditions and experiments were performed with permission 
of the Bavarian state. 
 
4.10 Isolation of RNA and reverse transcription 
   The High Pure RNA Isolation Kit (Roche) was used to isolate total RNA from human 
cancer cells according to the manufacturer’s instructions. Elution occurred by using 
50 µl elution buffer. Amount and quality of the RNA were determined using a Nanodrop 
spectrophotometer. cDNA was generated from 1 µg of total RNA per sample using 
anchored oligo(dT) primers (Verso cDNA synthesis Kit) following the manufacturer’s 
instructions. For the detection of mature miRNAs cDNA was generated from 300 ng 
total RNA per sample using the Universal cDNA Synthesis Kit from the miRCURY LNA 
Universal RT microRNA PCR Kit (Exiqon, 203300) according to the manufacturer´s 
instructions. As primers miRNA LNA PCR primers specifically for miR-34a/b/c (Exiqon: 
204486, 204005, 204407) and the respective control primer SNORD48 (Exiqon: 
203903) were used. 
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4.11 Luciferase assay 
   DLD-1 cells were seeded in 12-well format dishes at 1.5 x 105 cells/well and 
transfected with FuGene Reagent (Roche) for 48 hours with 100 ng of the indicated 
firefly luciferase reporter plasmid (pBV), 100 ng of the respective pcDNA3 vector and 
20 ng of Renilla reporter plasmid (pRL) as a normalization control. SW480 cells were 
seeded in 12-well format dishes at 3 x 105 cells/well and transfected for 72 hours with 
100 ng of the indicated firefly luciferase reporter plasmid, 20 ng of Renilla reporter 
plasmid as a normalization control and 25 nM of miR-34a pre-miRNA oligonucleotides 
(Ambion, PM11030), or a negative control oligonucleotides (Ambion, neg. control #1). 
HEK293T cells were seeded in 12-well format dishes at 1.5 x 105 cells/well and 
transfected with FuGene Reagent (Roche) for 48 hours. 100 ng of the indicated firefly 
luciferase reporter plasmid (pGL3), 500 ng of the pcDNA3 vector as indicated and 20 ng 
of Renilla reporter plasmid as a normalization control were used. The pGL3-SNAIL 
promoter constructs were kindly provided by Antonio Garcia de Herreros and Lionel 
Larue (Barbera et al, 2004). The analyses were performed with the Dual Luciferase 
Reporter assay kit (Promega) according to the manufacturer’s instructions. 
Luminescence intensities were measured with an Orion II luminometer (Berthold) in 96-
well format and analyzed with the SIMPLICITY software package (DLR). DLD-1 
colorectal cancer cells harboring a conditional ZNF281 allele and SW480 cells in 12-
well plates were transfected using FuGene Reagent (Roche) supplemented with 10 ng 
of Renilla luciferase control reporter plasmid, 100 ng Topflash or Fopflash luciferase 
reporter constructs containing either wild-type or mutant TCF binding sites (Veeman et 
al, 2003). The conditional ZNF281 allele was activated by addition of Doxycycline 
(DOX; 100 ng/ml) for 72 hours. Firefly and Renilla luciferase activities were measured 
72 hours after transfection using the Dual Luciferase Reporter assay kit (Promega) as 
mentioned above. 
 
4.12 Migration and invasion analysis in Boyden-chambers  
   DLD-1 and SW480 cells expressing DOX-inducible pRTR or pRTS vectors were 
cultured for the indicated periods in presence or absence of DOX [pRTR: 100 ng/ml; 
pRTS: 1 µg/ml]. Cells were deprived of serum (0.1%) for 48 hours before the analysis. 
To analyze migration 5 x 104 cells were seeded in the upper chamber (8.0 µm pore 
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size; Corning) in serum-free medium. To analyze invasion membranes were coated with 
Matrigel (BD Bioscience) at a dilution of 3.3 mg/ml in medium without serum. After 
coating 7 x 104 cells were seeded on Matrigel in the upper chamber. As chemo-
attractant 10% FCS was used in the lower chamber. Cultures were maintained for 
48 hours, then non-motile cells at the top of the filter were removed and the cells in the 
lower chamber were fixed with methanol and stained with DAPI. Either the number of 
cells per well or five different fields per condition were counted by microscopy. The 
relative invasion/migration was expressed relative to the control.  
 
4.13 NCI-60 database analysis 
   The NCI-60 dataset contains microarray expression analysis results of various human 
cancer cell lines derived from multiple tumor types (Shoemaker, 2006). Results derived 
from seven colon cancer cell lines were chosen for further analysis. 
 
4.14 Oncomine analysis 
   The Oncomine tool (Rhodes et al, 2004) was used in order to assess the differential 
expression of ZNF281 mRNA in human cancer datasets. The following settings were 
used: p-value of 0.05 and gene rank in the top 10% among all differentially expressed 
genes. For the listed analyses, the statistical results were provided by Oncomine and 
linked to a graphical representation of the original microarray dataset samples.  
 
4.15 Polymerase chain reaction (PCR) methods 
 
4.15.1 Colony PCR 
   The identity and orientation of the insert of bacterial cell clones was verified by colony 
PCR. For this 20µl PCR master mix containing vector and/or insert specific primers, 
dNTPs, 10x Vogelstein PCR buffer and FIREPol® DNA polymerase were prepared. 
Single colonies were picked from the LB-agar plate and transferred each into a single 
PCR tube. PCR cycling conditions were as exemplarily given: five minutes at 95°C, 
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followed by 25 cycles of 95°C for 20 seconds, 58°C for 30 seconds and 72°C for 
X minute/s (1 minute per 1 kb length of the expected PCR product). PCR fragment 
length was analyzed by supplementing the sample with loading dye and loading it to an 
agarose gel (percentage of the gel adjusted to the fragment length). 
 
4.15.2 PCR amplification from HDF DNA 
 
4.15.2.1 Cloning of 3´-UTR sequences 
   The full-length and shortened version of the 3´-UTR of the human ZNF281 mRNA 
containing the putative miR-34a binding site were PCR-amplified from genomic DNA 
from HDFs using specific primers to clone the full-length (fl) 3´-UTR and the 77 bp long 
version of the 3´-UTR (3´-UTR fragment). The resulting 3´-UTR or the 3´-UTR fragment 
were cloned into the shuttle vector pGEM-T-Easy (Promega) respectively. After excision 
with EcoRI and SpeI the respective 3´-UTRs were cloned into the pGL3-control-MCS 
(Welch et al, 2007) and were verified by sequencing. Oligonucleotides used for cloning 
and mutagenesis are given in chapter 3.5.2.3.  
 
4.15.2.2 Cloning of the ZNF281 promoter constructs 
   The human ZNF281 promoter (-1967/+34) containing the SNAIL binding sites (SBS) 
2+3 (SBS2+3) was PCR-amplified from genomic DNA from HDFs using specific primers 
adding NheI and EcoRI restriction sites to the ends of the PCR product. After restriction 
with NheI and EcoRI the respective promoter construct was cloned into the pBV-MCS 
and were verified by sequencing. Oligonucleotides used for cloning and mutagenesis 
are given in chapter 3.5.2.3. 
 
4.16 Protein isolation, SDS-PAGE and Western blot 
   Protein lysate generation, SDS-PAGE and Western blot analyses were performed 
according to standard protocols. Briefly, cells were lysed in RIPA lysis buffer (50 mM 
Tris/HCl, pH 8.0, 250 mM NaCl, 1% NP40, 0.5% (w/v) sodium deoxycholate, 
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0.1% sodium dodecylsulfate, complete mini protease inhibitor tablets (Roche)). Lysates 
were sonicated using a HTU SONI130 (G. Heinemann Ultraschall- und Labortechnik) 
for three consecutive five-second pulses with an intensity of 85% and centrifuged at 
16.060 g for 15 minutes at 4°C in order to separate the protein containing supernatant 
from any cell debris. The BCA Protein Assay Kit (Pierce, Thermo Scientific) was used to 
determine the protein concentrations according to the manufacturer’s instructions. The 
protein concentration was measured with a Varioskan Flash Multimode Reader using 
the SkanIt RE for Varioskan 2.4.3 software (Thermo Scientific). Afterwards, 30 to 80 µg 
of the respective protein lysates supplemented with Laemmlie buffer were denatured at 
95°C for five minutes and loaded on 10% or 12% SDS-acrylamide gels according to the 
protein size. A pre-stained protein ladder (Fermentas) served as size control and the 
separation of the proteins by electrophoresis was performed at 60-130 V in a Mini-
PROTEAN®-electrophoresis system (Bio-Rad) with Tris-glycine-SDS running buffer. 
Afterwards the proteins were transferred onto Immobilon PVDF membranes (Millipore) 
using Towbin buffer and the PerfectBlue™ SEDEC blotting system (Peqlab) and a EPS 
600 power supply (Pharmacia Biotech) constantly at 125 mA per gel and a maximum 
voltage of 10 V. Thereafter, the membranes were incubated for one hour in 5% skim 
milk/TBS-Tween20 (TBS-T) to block unspecific protein binding. Incubation with the 
primary antibodies (diluted in TBS-T) occurred at 4°C overnight. Horseradish-
peroxidase (HRP)-conjugated secondary antibodies were incubated for one hour at RT. 
In between, membranes were washed twice in TBS-T for 15 minutes each. ECL/HRP 
substrate (Immobilon) was added to the membrane. ECL signals were recorded using a 
CF440 Imager (Kodak). The polyclonal anti-ZNF281 antibody was generated by 
immunizing rabbits with a purified recombinant GST-ZNF281 fusion protein (amino 
acids 1-330) and purified by affinity chromatography with a Sulfo-Link (Pierce) coupled 
immunogen. Antibodies used here are listed in chapter 3.4. 
 
4.17 Quantification of Western blot signals 
   Intensities of protein expression signals generated by Western blot were quantified 
using the ImageJ software (Schneider et al, 2012). ImageJ is inspired by NIH Image 
and offers a processing and analysis program. Upon up-loading of the respective 
images it allows the user to carry out a calculation of area and pixel value statistics. The 
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resulting values were used for calculation of a ratio of the respective protein of interest 
and the loading control, whereas the quotient of the respective experimental control was 
set equal to one. 
 
4.18 Quantitative real-time PCR (qPCR) and Exiqon qPCR 
   Quantitative real-time PCR (qPCR) was performed by using the LightCycler 480 
(Roche) and the Fast SYBR Green Master Mix (Applied Biosystems) and β-actin or 
GAPDH as control as previously described in (Menssen & Hermeking, 2002). Only 
primer pairs resulting in a single peak in the melting curve analysis were used. A list of 
all qPCR-primers is provided in chapter 3.5.2.2. The qPCR results were analyzed using 
the ∆∆cp method (Livak & Schmittgen, 2001).  
qPCR for mature miRNAs was performed using the LightCycler 480 (Roche) and the 
Fast SYBR Green Master Mix Universal RT (Exiqon, 203450) according to the 
manufacturer’s instructions. 
 
4.19 Retroviral infections 
   For pBabe-SNAIL-VSV generation, SNAIL-VSV (Siemens et al, 2011), was cloned 
into the pBabe-empty vector. For retrovirus production, Phoenix-A packaging cells were 
transfected with pBabe-SNAIL-VSV (puromycin) or pBabe-empty vector (puromycin) 
using calcium phosphate transfection. 24 hours after transfection, retrovirus-containing 
supernatants were harvested, passed through 0.45 µm clarification filters (Millipore), 
and used to infect the respective cell lines four times in the presence of polybrene 
(8 µg/ml) in four hours intervals. After 48 hours, cells were selected by addition of 
2 µg/ml puromycin (Sigma) for five days. 
 
4.20 RNA interference 
   For RNA interference an episomal all-in-one vector system was employed 
(Epanchintsev et al, 2006). This vector allows the expression of miR-30-embedded 
microRNAs after addition of DOX. The target sequence for the respective ZNF281-
specific-microRNAs used was from the RNAi codex 
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(http://codex.cshl.edu: sequence 1: TCATCAAACCATACCAATA; sequence 2: 
TCTAAATGCTGAAATTAA). The non-silencing microRNA fragment was isolated from a 
commercial pSM2c vector (Expression ArrestTM, Cat. No. RHS1703, Open Biosystems). 
siRNAs (Ambion silencer siRNA negative control: #1 ID#4611; ZNF281-specific 
siRNAs: #1- ID#115950, #2- ID#3898; SNAIL-specific siRNA: ID#17124) were 
transfected at a final concentration of 10 nM for the indicated time-points using 
HiPerfect transfection reagent (Qiagen). 
 
4.21 Sequencing 
   Sanger sequencing was performed to verify DNA sequences. For this reaction the 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Life Technologies) was used according 
to the manufacturer’s protocol. One µg of DNA, 5 pmol of the respective primer, the 
BigDye Terminator and the buffer were mixed in a total reaction volume of 10 µl. PCR-
amplification was performed by 15 cycles of each ten seconds at 96°C, followed by 
90 seconds at 60°C. Afterwards the samples were cooled down to RT. In order to clean 
up the PCR reaction, the DyeEx 2.0 Spin Kit (Qiagen) was used according to the 
manufacturer’s instructions in a 5417C centrifuge (Eppendorf). Purified DNA was 
supplemented with Hi-Di formamide (Applied Biosystems) and loaded into an ABI3130 
genetic analyzer capillary sequencer (Applied Biosystems). Analysis of the data was 
done by using the 3130 Data Collection Software v3.0 and the sequencing analysis 
software 5.2 (Applied Biosystems).  
 
4.22 Site directed mutagenesis 
   The wild-type ZNF281 promoter construct was further used for mutagenesis of the 
SNAIL binding sites 2, 3 or 2+3. The sequence of the SNAIL binding sites was mutated 
from CACCTG to ACTCCT. This was achieved with the QuickChangeII Site-directed 
Mutagenesis Kit (Agilent Technologies) using the respective mutagenic primers and 
performing the mutagenic reaction according to the manufacturer’s instructions. 
Correctness of the plasmid sequences was verified by sequencing. Oligonucleotides 
used for cloning and mutagenesis are given in chapter 3.5.2.3. 
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4.23 Soft agar colony formation assay  
   To measure anchorage-independent cell growth, the bottom of a 12-well plate was 
coated with 700 µl base agar containing 0.8% low melt agarose (Lonza), which was 
then covered with 700 µl 0.4% agarose containing the respective cells and incubated for 
24 hours at 37°C and 5% CO2. 24 hours later 250 µl medium were added, 
supplemented with 10% FBS and either DOX [100 ng/ml] or water. Cells were 
incubated for 14 days changing the medium every three days. For determination of 
colony numbers cells were stained with 50 µl of 0.005% crystal violet per well for two 
hours and de-stained in PBS at 4°C overnight. Pictures were taken using an EOS 400D 
camera (Canon) and colonies were counted using image J software (Schneider et al, 
2012).  
 
4.24 Sphere formation assay 
   Cells were separated by treatment with trypsin after addition of DOX for 48 hours. For 
each triplicate 1 x 105 cells were seeded into a well of a 6-well-plate coated with 
attachment preventing poly(2-hydroxyethyl-metacrylate) (PolyHEMA, Sigma) in 5 ml 
sphere-medium (Yu et al, 2007). After seven days the resulting spheres were 
documented by phase-contrast microscopy at 100 x magnification and spheres were 
dissociated to single cells using a 0.05% Trypsin-EDTA solution. For quantification, 
1 x 104 cells/well were seeded in six wells of a PolyHEMA coated 96-well plate in Yu-
medium containing 1% methyl cellulose (Sigma) in the absence or presence of DOX. 
The number of colonies larger than 50 µm in diameter was counted after seven days. 
 
4.25 Statistical analysis 
   Unless noted otherwise each experiment was carried out in triplicates. A Student’s t-
test (unpaired, two-tailed) was used for calculation of significant differences between 
two groups of samples, with p<0.05 considered signiﬁcant. Asterisks generally indicate: 
*: p<0.05, **: p<0.01 and ***: p<0.001. For correlation analyses the SPSS software 
package 19 (SPSS Inc.) was used. Spearman rank correlation test was applied to the 
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NCI-60 data in order to correlate the ZNF281 mRNA expression with the expression of 
other mRNAs. 
 
4.26 Wound-healing assay 
   DLD-1 and SW480 cells harbouring a DOX-inducible ZNF281 allele or respective 
microRNAs were cultured for the indicated periods in the presence of DOX [100 ng/ml 
for pRTR vectors and 1 µg/ml for pRTS vector systems] or left untreated before 
applying the wound. Mitomycin C [10 ng/ml] was applied two hours before scratching 
using a Culture-Insert (IBIDI). To remove Mitomycin C and detached cells, cells were 
washed twice in Hank's balanced salt solution (HBSS) and medium containing DOX 
[100 ng/ml or 1 µg/ml] was added. Cells were allowed to close the wound for the 
indicated periods and images were captured on an Axiovert Observer Z.1 microscope 
connected to an AxioCam MRm camera using the Axiovision software (Zeiss) at the 
respective time-points.  
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5. RESULTS 
5.1 SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes 
epithelial-mesenchymal-transition 
   Previously, an interaction between c-MYC and ZNF281 proteins has been identified in 
a systematic analysis of c-MYC-associated protein complexes (Koch et al, 2007). 
ZNF281 was among the proteins, which were represented by the highest number of 
mass-spectrometric sequence reads, indicating that it is associated with a large fraction 
of c-MYC and presumably represents a significant regulator or effector of c-MYC. 
However, so far it is mainly unknown how ZNF281 expression itself is regulated and 
whether it participates in regulatory pathways, which might by relevant for c-MYC 
function and/or tumor biology. 
 
5.1.1 SNAIL regulates ZNF281 expression 
   In order to identify upstream regulators of ZNF281 the ZNF281 promoter sequence 
was inspected for binding sites of transcription factors, which might hint towards cancer-
relevant functions of ZNF281. Thereby, several E-Box motifs (CACCTG) in the ZNF281 
promoter were identified, which represent putative SNAIL binding sites (SBS, Figure 
7A). SNAIL is a known regulator of EMT (Batlle et al, 2000; Mauhin et al, 1993) and, 
similar to ZNF281, a zinc-finger-containing transcription factor (Nieto, 2002; Sanchez-
Tillo et al, 2012). Two of the SBSs were located ~500 and ~700 base pairs (bp) 
upstream of the transcription start site (TSS; Figure 7A and B). SBS2 and SBS4 are 
conserved between the human and mouse ZNF281 promoters, indicating functional 
relevance (Figure 7B). When SNAIL was ectopically expressed in DLD-1 colorectal 
cancer (CRC) cells using a Doxycycline (DOX) inducible episomal vector system an 
increase in the SNAIL occupancy of the ZNF281 promoter was detected by chromatin 
immunoprecipitation (ChIP) analysis at SBS2 and SBS3, whereas SBS1, 4 and 5 did 
not display increased binding of SNAIL (Figure 8A). Also endogenous SNAIL protein 
selectively occupied SBS2 and SBS3 in SW620 CRC cells (Figure 8B). 
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 Figure 7: The ZNF281 promoter contains putative SNAIL binding sites. (A) Scheme of 
the ZNF281 promoter and SNAIL binding sites (SBS). Grey arrows indicate SNAIL binding sites; 
black rectangles exons and the bar a qChIP amplicon for two SBSs at the same time. TSS: 
transcription start site. (B) Sequence alignment of the indicated SBS in the indicated species. 
 
 
Figure 8: SNAIL occupation at the ZNF281 promoter. Analysis of SNAIL binding to the 
ZNF281 promoter at the predicted SNAIL binding motifs. (A) ChIP analysis of DLD-1/pRTR-
SNAIL-VSV cells 24 hours after addition of DOX or left untreated using anti-VSV and anti-rabbit-
IgG antibodies for ChIP. Results are given as the mean +/- SD (n=3). (B) ChIP assay in SW620 
cells using an antibody against endogenous SNAIL. Results represent the mean +/- SD (n=3) of 
biological triplicates. Fold enrichment was calculated using the 2-∆∆cp formula with the isotype 
control IgG set to one. Detection of SNAIL binding to 16q22 served as negative control. A 
Student’s t-test was used with: ***: p<0.001. 
DLD-1/pRTR-SNAIL-VSV cells were generated by Helge Siemens. The ChIP assays were 
performed by Rene Jackstadt and the resulting material was used for the qChIP measurement 
in (A) and (B). 
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   Furthermore, ectopic SNAIL enhanced the expression of ZNF281 at the protein and at 
the mRNA level in DLD-1 cells (Figure 9A and B). SNAIL also induced ZNF281 
expression in SKBR3 breast cancer and MiaPaCa2 pancreatic cancer cells (Figure 9C). 
Therefore, the induction of ZNF281 by SNAIL is not restricted to a specific cell type. In 
order to determine whether ZNF281 is induced by SNAIL via the SBS motifs, a region 
encompassing 2 kbp upstream of the ZNF281 transcriptional start site was subjected to 
a dual reporter assay (Figure 10). Indeed, the wild-type reporter was induced by SNAIL, 
whereas binding site mutation of SBS2 abolished and SBS3 mutation decreased the 
responsiveness to SNAIL. Also a reporter with combined mutation of SBS2 and SBS3 
resulted in complete loss of responsiveness to SNAIL. A CDH-1 reporter was repressed 
by SNAIL in an SBS-dependent manner in this assay. 
 
Figure 9: Ectopic SNAIL regulates ZNF281 expression. (A) DLD-1/pRTR-SNAIL-VSV cells 
treated with DOX for the indicated periods or left untreated were subjected to Western blot 
analysis of the indicated proteins at the indicated time-points. (B) qPCR analysis of ZNF281 
mRNA levels using the cells described in (A) with values representing the mean +/- SD (n=3). A 
Student’s t-test was used. *: p<0.05 and **: p<0.01. (C) The breast cancer cell line SKBR3 and 
the pancreatic cancer cell line MiaPaCa2 were transduced with pBabe-SNAIL-VSV (SNAIL) or 
the respective control vector (ctrl.). SNAIL and ZNF281 proteins were detected by Western blot 
analysis. In (C) the transduction with pBabe vectors and the Western blot analysis were 
performed by Rene Jackstadt.  
In the Western Blot analyses α-tubulin served as loading control. Relative densitometric 
quantifications are indicated; ZNF = ZNF281, α-tub = α-tubulin. 
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 Figure 10: SNAIL regulates ZNF281 expression directly via SBS2 and SBS3. Luciferase 
assay in DLD-1 cells 48 hours after transfection of pCDN3-VSV (ctrl.) or pCDNA3-SNAIL-VSV 
(SNAIL) vectors and the indicated pBV-ZNF281 promoter constructs (ZNF281) or the respective 
pXP2-E-cadherin/CDH-1 vectors as system controls (wt: wild-type, mut: mutated). A Student’s t-
test was used with: **: p<0.01 and ***: p<0.001. 
 
   ZNF281 displayed higher expression levels in CRC cell lines with mesenchymal 
features such as Colo320, SW480 and SW620, than in CRC cells with an epithelial 
phenotype such as HT29, DLD-1 and HCT-15 (Figure 11). ZNF281 expression 
correlated positively with SNAIL and Vimentin and inversely with E-cadherin expression 
(Figure 11). Moreover, analysis of publicly available mRNA expression profiles obtained 
from seven colorectal cancer cell lines (COLO205, HCC2998, HCT116, HCT15, HT29, 
KM12, SW620) within the NCI-60 panel (Shoemaker, 2006) confirmed a significant 
correlation between ZNF281 and the EMT markers SNAIL, Vimentin and Fibronectin-1 
(Table 2). Taken together, these results suggested that the induction of ZNF281 by 
SNAIL might be an important component of the EMT program induced by SNAIL. 
Indeed, when ZNF281 was down-regulated using two different siRNAs the induction of 
EMT by SNAIL was prevented in DLD-1 cells (Figure 12A and B). Also the loss of the 
scaffold protein E-cadherin from the outer membrane, which is typical for EMT, was 
prevented by simultaneous siRNA-mediated down-regulation of ZNF281. Therefore, 
ZNF281 is required for SNAIL-induced EMT. 
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 Figure 11: Expression comparison of various proteins in six different CRC cell lines. 
Western blot analysis of the indicated proteins in CRC cell lines. “epi.” = cells with epithelial, 
“mes.” = cells with mesenchymal phenotype. Detection of β-actin served as a loading control. 
 
 
Table 2: Correlation analyses of the mRNA expression of ZNF281 and selected target 
genes in seven CRC cell lines of the NCI-60 panel. Expression data obtained from the NCI-
60 database representing seven different colorectal cancer cell lines were subjected to 
correlation analyses. The table displays the correlation between ZNF281, SNAIL, Vimentin 
(VIM) and Fibronectin-1 (FN-1) mRNA expression. The significance of the calculated 
correlations was determined by a 2-tailed t-test and is indicated as: * = significant at 0.05 level; 
** = significant at 0.01 level. 
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 Figure 12: Requirement of ZNF281 for SNAIL-induced EMT. DLD-1/pRTR-SNAIL-VSV cells 
were treated with DOX (+) or left untreated (-) for 96 hours and simultaneously transfected with 
the indicated siRNAs. (A) The indicated proteins were detected by Western blot analysis. 
Detection of α-tubulin served as a loading control. Relative densitometric quantifications are 
indicated. E-cad = E-cadherin; α-tub = α-tubulin. (B) Two upper panels: Representative phase-
contrast pictures (P/C) of the cells described in (A). 200 x magnification. Two lower panels: 
Detection of E-cadherin by indirect immunofluorescence and confocal microscopy. Nuclear DNA 
was visualized by DAPI staining. 200 x magnification. Scale bars represent 25 µm. 
 
5.1.2 miR-34a directly regulates ZNF281 expression 
   The differences between the increase in ZNF281 protein levels and the minor 
regulation of mRNA levels after ectopic SNAIL expression suggested the possibility of 
an additional translational regulation mediated by miRNAs. Inspection of the ZNF281 
3´-UTR using TargetSCAN and Miranda algorithms (Grimson et al, 2007; John et al, 
2004) has revealed a conserved miR-34 seed-matching sequence (Figure 13).  
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Figure 13: Putative miR-34 binding sites in the ZNF281 3’UTR. Schematic depiction of the 
miR-34 seeds (blue) and seed-matching sequences (red) in the 3´-UTR of the ZNF281 mRNA 
and phylogenetic conservation among species (modified from www.targetscan.org). The 
position of the miR-34 seed-matching sequence in the ZNF281 3’-UTR is depicted as a black 
vertical bar.  
 
Since it has previously been shown that the miR-34a and miR-34b/c genes are directly 
repressed by SNAIL (Siemens et al, 2011), it was hypothesized that at least part of the 
increase in ZNF281 expression observed after SNAIL induction might be due to a 
repression of miR-34 genes. Indeed, ectopic miR-34a expression resulted in the down-
regulation of endogenous ZNF281 expression on the protein and mRNA level in SW480 
CRC cells (Figure 14A and B). This was also observed in MiaPaCa2 pancreatic cancer 
cells (Figure 14C and D). Therefore, the regulation of ZNF281 by miR-34a is not 
restricted to CRC cells. Furthermore, reporter constructs containing the entire 3´-UTR of 
ZNF281 (720 bp) or a 77 bp fragment including the seed-matching sequence were 
repressed by co-transfection of pre-miR-34a, but not when the seed-matching 
sequence was mutated, demonstrating that it mediates repression by miR-34a (Figure 
15A and B). The induction of ZNF281 by SNAIL was prevented by concomitant 
transfection of pre-miR-34a (Figure 16). Therefore, the previously documented 
repression of the miR-34a gene by SNAIL (Siemens et al, 2011) is presumably 
necessary for the SNAIL-mediated increase in ZNF281 expression. In summary, these 
results demonstrate that ZNF281 is directly regulated by miR-34a and that SNAIL 
induces ZNF281, at least in part, by repressing miR-34a. 
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 Figure 14: miR-34a represses ZNF281 expression. (A) Western blot analysis of endogenous 
ZNF281 protein levels in SW480 cells harboring a pRTR-pri-miR-34a vector after treatment with 
DOX for the indicated periods. Relative densitometric quantifications are indicated. ZNF = 
ZNF281; α-tub = α-tubulin. (B) Analysis of ZNF281 mRNA levels in the cells corresponding to 
(A). Data represent the mean +/- SD (n=3). (C) MiaPaCa2 cells harboring a bicistronic pRTS-
pri-miR-34a vector were treated with DOX for 72 hours or left untreated. The indicated proteins 
were detected by Western blot analysis. (D) qPCR analysis to determine the expression levels 
of the indicated mRNAs using the cells described in (C). Expression was normalized to GAPDH 
expression.  
For the Western blot analyses α-tubulin served as a loading control. In (B) and (D) a Student’s t-
test was applied. **: p<0.01 and ***: p<0.001.  
The cell lysates described in (A) and the respective cDNAs in (B) were provided by Helge 
Siemens. The cells used in (C) and (D) are described in (Lodygin et al, 2008). 
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 Figure 15: miR-34a represses the ZNF281 reporter activity. (A) Mutagenesis of the ZNF281 
3´-UTR. Black vertical bars indicate the remaining matches of the miR-34a seed (shaded black) 
with the miR-34 seed-matching sequence (shaded gray) in the ZNF281 3´-UTR sequences 
(wt: wild-type, mut: mutated). (B) Dual luciferase reporter assay in SW480 cells 72 hours after 
transfection with pre-miR-34a or control oligonucleotides and the empty pGL3 vector or pGL3 
harboring the indicated 3´-UTR-reporter constructs (fl: full-length). A 3´-UTR-reporter of the 
known miR-34a target TPD52 served as a positive control. Data represent the mean +/- SD 
(n=3). A Student’s t-test was used. *: p<0.05 and ***: p<0.001. 
 
 
Figure 16: Transfection of pre-miR-34a oligonucleotides prevented the SNAIL-mediated 
induction of ZNF281. Western blot analysis of the indicated proteins in DLD-1 cells harboring a 
pRTR-SNAIL-VSV vector transfected with the indicated oligonucleotides for 60 hours and 
treated with DOX or left untreated for 36 hours prior to cell lysis. Detection of α-tubulin served 
as a loading control.  
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5.1.3 p53 represses ZNF281 via miR-34a 
   Since the miR-34 genes represent direct p53 targets, it was of further interest whether 
p53 represses ZNF281 expression via inducing miR-34a. Indeed, ectopic expression of 
p53 resulted in a decrease of ZNF281 at the protein and mRNA level (Figure 17A and 
B). As expected, miR-34a/b/c levels were increased upon p53 activation (Figure 18A 
and B), which is likely to mediate the decrease in ZNF281 protein expression. Since 
miR-34b/c is expressed at least at 10 fold lower levels in CRC and CRC cell lines 
compared to miR-34a (Siemens et al, 2013; Toyota et al, 2008) further analyses were 
focused on miR-34a. The recovery of ZNF281 mRNA expression by 72 hours of ectopic 
p53 expression (Figure 17B) is presumably due to the declining expression of ectopic 
p53 and therefore reduced pri-miR-34 induction at this time-point (Figure 17A and 
Figure 18B). Nonetheless, ZNF281 protein was still down-regulated 72 hours after 
activation of p53 (Figure 17A). In order to determine whether down-regulation of 
ZNF281 is a result of reduced SNAIL expression caused by direct interaction of SNAIL 
with p53 (Lim et al, 2010) or due to p53-induced miR-34, direct interference with miR-
34a function using antagomirs was performed. Indeed, miR-34a–specific antagomirs 
largely abolished the down-regulation of ZNF281 after p53 induction, whereas a control 
antagomir did not affect the repression of ZNF281 by p53 (Figure 19). The remaining 
minor repression of ZNF281 may be due to p53-induced miR-34b and -c, which are 
presumably not affected by the miR-34a-specific antagomir used here.  
 
 
Figure 17: p53 represses ZNF281 mRNA and protein levels. SW480 cells harboring a pRTR-
p53-VSV vector treated with DOX for the indicated periods or left untreated were used. (A) 
Western blot analysis of endogenous ZNF281 expression at the indicated time-points. (B) 
Ectopic p53 was expressed for the indicated periods before RNA was isolated and subjected to 
qPCR analysis. The values represent the mean +/- SD (n=3). Student’s t-test was used. 
**: p<0.01. The SW480/pRTR-p53-VSV cells were generated by Sabine Hünten. 
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 Figure 18: p53 induces miR-34. SW480/pRTR-p53-VSV vector treated with DOX for the 
indicated periods or left untreated were used. (A) Analysis of mature miR-34a/b/c expression 
levels 48 hours after addition of DOX to induce p53 or left untreated by qPCR. (B) qPCR 
analysis of pri-miR-34a mRNA levels at the indicated time-points. In (A) and (B) values 
represent the mean +/- SD (n=3) and a Student’s t-test was used with: *: p<0.05 and 
***: p<0.001. 
 
 
Figure 19: Transfection of a miR-34a-specific antagomir abolishes the p53-mediated 
repression of ZNF281. SW480 cells harboring a pRTR-p53-VSV vector were transfected with 
the respective oligonucleotides for 72 hours and treated with DOX for the last 48 hours before 
cell lysis or left untreated as indicated. The indicated proteins were detected by Western blot 
analysis. Detection of β-actin served as a loading control and was used for relative 
densitometric quantifications. ZNF = ZNF281. 
 
   Additionally, the expression of ZNF281 was analyzed in HCT116 p53 +/+ cells and in 
the isogenic clone with homozygous deletion of p53 resembling p53 inactivation in 
tumors. HCT116 p53 +/+ cells expressed lower endogenous levels of ZNF281 protein 
and mRNA than p53-deficient cells (Figure 20A and B). As previously described 
(Siemens et al, 2011), the expression of the SNAIL protein was elevated in the HCT116 
p53 -/- cells (Figure 20A). When SNAIL was down-regulated using a SNAIL-specific 
siRNA the expression of ZNF281 protein was only decreased to a minor extent in p53-
deficient HCT116 cells (Figure 20C). Therefore, the increase in ZNF281 expression is 
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presumably mainly due to the decrease in miR-34a expression in p53-deficient cells 
(Figure 20B). Taken together, these results show that miR-34a represents an important 
mediator in the repression of ZNF281 by p53. 
 
 
Figure 20: Regulation of ZNF281 and SNAIL in HCT116 p53 +/+ and -/- cells. (A) Detection 
of the indicated proteins by Western blot analysis in HCT116 p53 +/+ and p53 -/- cells. (B) 
qPCR analysis of the ZNF281 and pri-miR-34a mRNA expression in HCT116 p53 +/+ and  
p53 -/- cells. (C) Western blot analysis of the indicated proteins in HCT116 p53 -/- cells 96 hours 
after transfection of a SNAIL-specific siRNA.  
In (A) and (C) detection of α-tubulin served as a loading control and was used for relative 
densitometric quantifications in (C). ZNF = ZNF281; α-tub = α-tubulin. In (B) values represent 
the mean +/- SD (n=3). A Student’s t-test was used. ***: p<0.001.  
The cDNAs used in (B) were provided by Sabine Hünten. 
 
5.1.4 ZNF281 induces EMT, migration and invasion 
   Since ZNF281 expression was induced by SNAIL and required for SNAIL-induced 
EMT, it was determined whether ectopic expression of ZNF281 is sufficient to promote 
EMT. For this purpose a pool of DLD-1 cells harboring an episomal pRTR construct that 
allows the DOX-inducible expression of ZNF281 was generated. After addition of DOX 
more than 90% of the cells were positive for eGFP (Figure 21A), which is expressed 
from a bidirectional promoter also driving the expression of ZNF281 (Figure 21B-C). 
After induction of ectopic ZNF281 expression DLD-1 cells changed from an epithelial 
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morphology (dense islands of cobblestone-shaped cells) to a mesenchymal morphology 
with spindle-shaped cells forming protrusions and displaying a scattered growth pattern 
(Figure 21D). This was reminiscent of the effect of ectopic SNAIL expression observed 
in DLD-1 cells before (Siemens et al, 2011). Also molecular markers of EMT were 
regulated by the expression of ZNF281 (Figure 22). The distinct membrane-bound 
expression of E-cadherin in DLD-1 cells was lost upon ZNF281 activation (Figure 22 
upper panel). Furthermore, ZNF281-expressing cells displayed an increased 
cytoplasmic expression of the mesenchymal marker Vimentin (Figure 22 middle panel). 
In addition, F-actin, which forms stress fibers (Moreno-Bueno et al, 2009), was 
relocated from the membrane to the cytoplasm (Figure 22 lower panel). 
 
 
Figure 21: Ectopic expression of ZNF281 in DLD-1 cells results in morphological 
changes. DLD-1 cells, which harbor a bicistronic pRTR-vector expressing eGFP and ZNF281-
VSV were treated with DOX for the indicated periods or left untreated. (A) Flow cytometric 
determination of the frequency of cells with inducible expression of eGFP in DLD-1 cell pools 
48 hours after addition of DOX. (B) Detection of the indicated proteins by Western blot analysis 
at the respective time-points using the cells described in (A). Detection of α-tubulin served as a 
loading control. (C) ZNF281 mRNA levels were determined by qPCR analysis using the 
indicated cells and time-points. Error bars represent +/- SD (n=3). A Student’s t-test was applied 
with ***: p<0.001. (D) Representative phase-contrast (P/C) pictures of the cells treated with 
DOX or left untreated for 96 hours. 200 x magnification. The scale bar represents 25 µm. 
61
 Figure 22: Regulation of epithelial and mesenchymal markers by ZNF281. DLD-1 cells 
harboring a pRTR-ZNF281-VSV vector treated with DOX for 96 hours or left untreated were 
analyzed. Confocal laser-scanning microscopy of E-cadherin, Vimentin and F-actin proteins 
detected by indirect immunofluorescence. Nuclear DNA was visualized by DAPI staining. 
200 x magnification. The scale bars represent 25 µm. 
 
   Subsequently, it was determined whether ectopic ZNF281 expression influences 
cellular migration and invasion, since EMT previously has been linked to increased 
migration and invasion (reviewed in (Christiansen & Rajasekaran, 2006)). In a wound-
healing assay ectopic ZNF281 expression resulted in a minor, but reproducible increase 
in the closure of a scratch in a confluent layer of DLD-1 cells (Figure 23A) compared to 
the controls (Figure 23A and Figure 24D). When migration and invasion were examined 
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in Boyden-chamber assays the effect of ectopic ZNF281 expression was more 
pronounced (Figure 23B and C). Furthermore, ectopic expression of ZNF281 
significantly enhanced the ability of DLD-1 cells to form colonies in soft agar 
(Figure 23D).  
 
 
Figure 23: Ectopic expression of ZNF281 influences cellular migration and invasion of 
DLD-1 cells. DLD-1 cells harboring a pRTR-ZNF281-VSV vector were used for the 
experiments. (A) Cells were treated with DOX or left untreated for 48 hours before the scratch 
was applied. Left panel: representative pictures of the wound areas at the indicated time-points 
after scratching. 100 x magnification. Right panel: results represent the average (%) of wound 
closure determined by the final width of the scratch in three independent wells. Error bars 
represent +/- SD (n=3). Boyden-chamber assays of cellular migration (B) or invasion (C). The 
cells were cultivated in the presence or absence of DOX for 72 hours with serum starvation for 
the last 48 hours. To analyze invasion, membranes were coated with Matrigel. After 48 hours 
cells were fixed and stained with DAPI. The average number of cells per well was counted in 
three different inserts. Relative invasion or migration is expressed as the value of treated cells 
to control cells with controls set as one. (D) The respective cells were subjected to a soft-agar 
assay and treated with DOX or left untreated. Two weeks after seeding the resulting colonies 
were stained with crystal violet. Results represent the mean number of colonies in soft agar per 
well +/- SD (n=3).  
(A-D) A Student’s t-test was used. **: p<0.01 and ***: p<0.001.  
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   The addition of DOX to DLD-1 cells harboring an empty vector control did not result in 
EMT-related morphological changes or significant effects in the above mentioned 
assays (Figure 24A-D). The effects of ectopic ZNF281 were not due to increased 
proliferation, since ZNF281 activation had a slight anti-proliferative effect (Figure 25), 
which has also been described before for other EMT-TFs such as SNAIL (Peinado et al, 
2007). Taken together, these results show that ectopic expression of ZNF281 is 
sufficient to mediate EMT and to enhance migration, invasion and anchorage 
independent growth.  
 
 
Figure 24: Expression of the vector control in DLD-1 cells does not result in 
morphological or migratory changes. DLD-1 cells harboring the empty vector control were 
used for the experiments. (A) Representative phase-contrast pictures of the cells 96 hours after 
treatment with DOX or left untreated. 200 x magnification. (B) Western blot analysis of the 
indicated proteins after addition of DOX for the indicated periods. Detection of α-tubulin served 
as a loading control. (C) Confocal microscopy of E-cadherin protein visualized by indirect 
immunofluorescence. Nuclear DNA was visualized by DAPI staining. 200 x magnification. (D) 
Analysis of cell migration using a wound healing assay. The cells were treated with DOX or left 
untreated 48 hours before a scratch was applied. Results represent the average percentage of 
closed wound area in three independent wells. The error bars represent +/- SD (n=3). A 
Student’s t-test was applied with p>0.05 being considered non-significant (n.s.).  
In (A) and (B) the scale bars represent 25 µm.  
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 Figure 25: ZNF281 induction leads to a diminished proliferation capacity of the cells. 
Analyses of DLD-1/pRTR-ZNF281-VSV cells. (A) Cell numbers were determined after induction 
of ectopic ZNF281 expression by addition of DOX for the indicated periods. (B) Analysis of cell 
cycle distribution by flow cytometric determination of DNA content of cells treated with DOX for 
48 hours or left untreated. (C) Phase-contrast pictures after DOX addition for 48 hours or left 
untreated. Cells were kept in normal medium supplemented with 10% FCS (+ FCS) or in 
medium supplemented with 0.1% FCS (- FCS). The scale bar represents 25 µm. (D) Cell cycle 
analysis by flow cytometry as in (B) after addition of DOX for 48 hours in medium with 0.1% 
serum.  
In (A), (B) and (D) error bars represent +/- SD (n=3). A Student’s t-test was applied. **: p<0.01 
and ***: p<0.001. 
 
 
 
 
 
 
 
65
5.1.5 Transcriptional regulation of EMT markers by ZNF281 
   Next, it was determined whether ZNF281 also induces changes in the expression of 
genes previously implicated in the transcriptional program of EMT. After activation of 
ectopic ZNF281 expression in DLD-1 cells an up-regulation of SNAIL was observed at 
the protein and mRNA level (Figure 26A-B). In addition, the mesenchymal markers 
SLUG, ZEB-1 and Fibronectin-1 were induced after ectopic ZNF281 expression in the 
DLD-1 CRC cells (Figure 26B). In line with the indirect immunofluorescence results as 
shown above in Figure 22 (upper panel) E-cadherin/CDH-1 was repressed at the 
protein level after induction of ZNF281 (Figure 26A), whereas expression of CDH-1 
mRNA was not significantly affected by ZNF281 (Figure 27).  
 
 
Figure 26: ZNF281 regulates genes implicated in the EMT process. DLD-1 cells harboring a 
pRTR-ZNF281-VSV vector treated with DOX or left untreated were analyzed. (A) Western blot 
detection of the indicated proteins after ectopic expression of ZNF281 for the indicated periods. 
Detection of α-tubulin served as a loading control and was used for relative densitometric 
quantifications. E-cad = E-cadherin, α-tub = α-tubulin. (B) Expression of the indicated mRNAs 
was determined by qPCR analyses. Results represent the mean +/- SD (n=3). A Student’s t-test 
was used. *: p<0.05, **: p<0.01 and ***: p<0.001. 
66
 Figure 27: ZNF281 represses epithelial genes. DLD-1/pRTR-ZNF281-VSV cells treated with 
DOX for the indicated time-points or left untreated were analyzed. Expression of the indicated 
mRNAs was determined by qPCR analyses. Results represent the mean +/- SD (n=3). A 
Student’s t-test was used. **: p<0.01 and ***: p<0.001. 
 
   However, when ZNF281 was expressed in HT29 CRC cells E-cadherin was 
repressed on both the protein and mRNA level (Figure 28A and C). Therefore, the 
regulation of EMT markers by ZNF281 is at least partially dependent on the cell line 
analyzed. Other epithelial markers such as OCLN and CLDN-7 were repressed on the 
mRNA level in DLD-1 and HT29 cells (Figure 27 and Figure 28C), which is a 
characteristic of EMT (Ikenouchi et al, 2003; Martinez-Estrada et al, 2006), along with 
increased migratory and invasive capacities upon ectopic ZNF281 expression in HT29 
cells (Figure 28D and E). Furthermore, ectopic ZNF281 expression resulted in the 
down-regulation of a number of additional epithelial marker genes, encoding 
components of tight junctions (ZO-1/3, CLDN-1), adherens junctions (CDH-3) as well as 
desmosomes (PKP2, DSP) (Figure 29), as previously shown for ZEB2 (Vandewalle et 
al, 2005). Since SNAIL is a potent inducer of EMT, we determined whether the up-
regulation of SNAIL by ZNF281 is mediated by direct occupancy of the SNAIL promoter. 
ZNF281 is known to occupy GC-rich DNA sequences, as previously shown for the 
ODC1 promoter (Law et al, 1999; Lisowsky et al, 1999). Similar GC-rich sequences are 
present in the SNAIL promoter (Figure 30A). When these regions were analyzed by a 
ZNF281-specific ChIP occupancy by ectopic and endogenous ZNF281 was detected in 
the vicinity of the SNAIL TSS (Figure 30B and C). The highest occupancy by ZNF281 
protein was detected in a region encompassing the SNAIL TSS itself and ~600 bp 
upstream.   
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 Figure 28: ZNF281 regulates epithelial and mesenchymal genes and influences motility in 
HT29 cells. HT29/pRTR-ZNF281-VSV cells were treated with DOX or left untreated for the 
indicated periods to activate ZNF281-VSV expression. (A) Western blot analysis of the indicated 
proteins. Detection of β-actin served as a loading control. (B) qPCR analysis of the ZNF281 
mRNA. The results represent the mean +/- SD (n=3). (C) qPCR analysis of the indicated 
mRNAs after ectopic expression of ZNF281 for the indicated periods. The results represent the 
mean +/- SD (n=3). (D) Cells were subjected to a wound healing assay. The cells were treated 
with DOX or left untreated for 72 hours before the scratch was applied. Wound healing was 
monitored at 0 and 48 hours. Results represent the mean percentage of the closed wound area 
in three independent wells +/- SD (n=3). (E) Boyden chamber-assays of cellular migration and 
invasion. Cells were cultivated in the presence or absence of DOX for 72 hours with serum 
starvation for the last 48 hours. For analysis of invasion the Boyden chambers were coated with 
Matrigel. After 48 hours cells were fixed and stained with DAPI. The average number of cells 
per well was counted in three different inserts. Relative migration and invasion is expressed as 
the ratio of treated cells to control cells with control set as one. 
In (B-E) a Student’s t-test was used. *: p<0.05, **: p<0.01 and ***: p<0.001. 
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 Figure 29: ZNF281 represses epithelial genes in DLD-1 cells. DLD-1 cells harboring a 
pRTR-ZNF281-VSV vector treated with DOX or left untreated were analyzed. Expression of the 
indicated mRNAs was determined by qPCR analyses. Results represent the mean +/- SD (n=3). 
A Student’s t-test was used. *: p<0.05, **: p<0.01 and ***: p<0.001. 
 
 
 
 
Figure 30: ZNF281 occupies the SNAIL promoter. (A) Schematic depiction of the SNAIL 
promoter. Amplicons (black bars) used for ChIP analysis, exons (black rectangles) and the TSS 
(transcription start site) are indicated. (B) ChIP assay of DLD-1/pRTR (ctrl.) or DLD-1/pRTR-
ZNF281-VSV (ZNF281) cells 24 hours after addition of DOX using anti-VSV and anti-rabbit-IgG 
antibodies. The previously described ZNF281 occupancy at the ODC1 promoter served as 
positive control. Results represent the percentage of input chromatin of induced versus control 
cells +/- SE (n=2). (C) ChIP assay in SW620 cells using an antibody against the endogenous 
ZNF281 protein (ZNF281) and the respective IgG control (IgG). Results represent the mean +/- 
SD (n=3). 
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   A set of deletion constructs of the human SNAIL promoter (Barbera et al, 2004) was 
used to determine the regions mediating the regulation by ZNF281 in a reporter assay. 
The activation of the SNAIL promoter was most dominant for the -869/+59 bp reporter 
(Figure 31), which was in line with the dominant binding of ectopic ZNF281 to a region 
~ 600 bp upstream of the TSS in the ChIP assay (Figure 30B). Unexpectedly, the longer 
-1558/+92 bp construct resulted in a weaker response to ZNF281, which may be due to 
repressive elements or binding sites for other transcription- or co-factors in the region 
between -869 and -1558 bp. Also the decreasing activity of further truncations indicates 
that the predominant region of ZNF281 binding is located between 514 bp and 869 bp 
upstream of the SNAIL TSS. Another, but less effective, binding region is presumably 
located closer to the TSS as also suggested by the ChIP results (Figure 30B and 
Figure 31). Occupancy by endogenous and ectopic ZNF281 was also detected in the 
promoter regions of CDH-1, OCLN and CLDN-7 (Figure 32A and B). 
   When SNAIL was down-regulated by RNA interference in DLD-1 cells ectopically 
expressing ZNF281 morphological changes associated with EMT were not observed 
(Figure 33A and B). Moreover, E-cadherin persisted at the cell-membrane, whereas co-
transfection of a control siRNA did not prevent its relocalization (Figure 33B). Therefore, 
ZNF281-induced EMT is mediated, at least in part, by SNAIL. In summary, these 
analyses show that ZNF281 directly regulates the expression of a subset of EMT 
regulators and effectors. The requirement of SNAIL for ZNF281-induced EMT suggests 
that at least some of these regulations are mediated and/or enhanced via the induction 
of SNAIL. Furthermore, ZNF281 directly induces SNAIL, which itself activates ZNF281 
expression, thereby forming a positive feedback loop, which may enforce and stabilize 
the process of EMT. 
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Figure 31: ZNF281 regulates the activity of SNAIL promoter reporters. The indicated pGL3-
SNAIL promoter plasmids were co-transfected with pcDNA3-VSV (ctrl.) or pcDNA3-ZNF281-
VSV (ZNF281) plasmids into HEK293T cells, which were subjected to a luciferase reporter 
assay after 48 hours. A Student’s t-test was used. *: p<0.05, **: p<0.01 and ***: p<0.001. 
 
 
 
 
Figure 32: ZNF281 occupies promoters of epithelial genes. (A) ChIP assay of DLD-1/pRTR 
(ctrl.) or DLD-1/pRTR-ZNF281-VSV (ZNF281) cells 24 hours after addition of DOX using anti-
VSV and anti-rabbit-IgG antibodies. (B) ChIP assay in SW620 cells using an antibody against 
the endogenous ZNF281 protein (ZNF281) and the respective IgG control (IgG). ZNF281 
occupancy is shown at the indicated promoters or chromosomal region 16q22, which served as 
negative control.  
In (A) and (B) results represent the mean +/- SD (n=3). 
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 Figure 33: SNAIL mediates ZNF281-induced EMT. (A) DLD-1/pRTR-ZNF281-VSV cells were 
transfected with a SNAIL-specific siRNA or the respective control (ctrl.) for 96 hours and treated 
with DOX or left untreated for 72 hours. Analysis of the indicated proteins by Western blot. 
Detection of β-actin served as a loading control. (B) Representative phase-contrast (P/C) 
images of cells analyzed in (A). 200 x magnification. Lower two panels: Detection of E-cadherin 
by indirect immunofluorescence 96 hours after transfection of the indicated siRNAs and 
treatment of DOX or left untreated as in (A) using confocal laser-scanning microscopy. Nuclear 
DNA was visualized by DAPI staining. 200 x magnification. Scale bars represent 25 µm.  
 
5.1.6 ZNF281 regulates β-catenin localization and activity as well as 
stemness 
   Interestingly, ectopic expression of ZNF281 in DLD-1 cells resulted in the 
translocation of β-catenin from the outer cell membrane to the nucleus (Figure 34), 
which is another characteristic of EMT (Brabletz et al, 2005b). Although, β-catenin 
mRNA and protein levels changed only slightly upon ZNF281 expression (Figure 35A 
and B), a significant increase in the transcriptional activity of β-catenin/TCF4 was 
observed after ZNF281 expression in DLD-1 and SW480 cells in a reporter assay 
(Figure 35C).  
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 Figure 34: ZNF281 regulates β-catenin localization. DLD-1 cells harboring a pRTR-ZNF281-
VSV vector were treated with DOX for 96 hours to activate ZNF281-VSV expression or left 
untreated. Detection of β-catenin by indirect immunofluorescence and confocal microscopy. 
Nuclear DNA was visualized by DAPI staining. 200 x magnification. The scale bar represents 
25 µm. 
 
 
 
Figure 35: ZNF281 increases β-catenin activity. DLD-1/pRTR-ZNF281-VSV cells were 
treated with DOX for the indicated time-periods to activate ZNF281-VSV expression or left 
untreated. (A) Western blot analysis of the indicated proteins. Detection of β-actin served as a 
loading control. (B) qPCR analyses with results represented as mean values +/- SD (n=3) (C) 
Left: TOPflash reporter assay in the indicated cell line after addition of DOX for 48 hours and 
concomitant transfection with TOP/FOP vectors. Right: TOPflash reporter assay of SW480 cells 
transfected with TOP/FOP vectors and control vector (ctrl.) or pcDNA3-ZNF281-VSV vector 
(ZNF281; as indicated) for 48 hours. Results represent the mean +/- SD (n=3).  
In (B) and (C) a Student’s t-test was used. *: p<0.05, **: p< 0.01 and ***: p<0.001. 
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   Axin2 negatively regulates the WNT/β-catenin/TCF4 signaling pathway by promoting 
phosphorylation and degradation of β-catenin/TCF4 via a multi-protein complex 
including APC and GSK3β (Lustig et al, 2002). Therefore, decreased levels of inhibitory 
Axin2 might result in the translocation of β-catenin to the nucleus. Indeed, Axin2 mRNA 
was repressed upon ectopic expression of ZNF281 (Figure 36A). Furthermore, we 
detected increased binding of ZNF281 at the Axin2 promoter, which harbors GC-rich 
regions representing potential binding sites for ZNF281 (Figure 36B and C). It is 
conceivable that a direct repression of Axin2 by ZNF281 may contribute to the 
increased activity of β-catenin/TCF4. In addition, the loss of E-cadherin from the cell-
membrane may contribute to the activation of β-catenin/TCF4 after ZNF281 activation. 
In line with the increase of β-catenin/TCF4 activity LGR5 and CD133, which are known 
β-catenin target genes (Carmon et al, 2012; Fan et al, 2010; Glinka et al, 2011; Katoh & 
Katoh, 2007), were induced after ectopic expression of ZNF281 in DLD-1 cells 
(Figure 36A). qChIP analysis revealed ZNF281 occupancy at the LGR5 promoter, but 
not at the CD133 promoter (Figure 36B and C). Since LGR5 and CD133 represent 
markers for putative cancer stem cells (Barker et al, 2007; Munoz et al, 2012; Zhu et al, 
2009) the activation of ZNF281 may be accompanied by the acquisition of stem cell 
traits. Indeed, ectopic ZNF281 expression significantly enhanced the formation of 
colono-spheres of non-adherent DLD-1 cells (Figure 37A and B). Taken together, 
ZNF281 enhances β-catenin activity and stemness of tumor cells. Both effects may 
contribute to metastases formation. 
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 Figure 36: ZNF281 regulates β-catenin targets. (A) qPCR analyses of DLD-1 pRTR-ZNF281-
VSV cells with results depicted as the mean +/- SD (n=3). A Student’s t-test was used. 
*: p<0.05, **: p<0.01 and ***: p<0.001. (B) qChIP assay in DLD1/pRTR and DLD-1/pRTR-
ZNF281-VSV cells 24 hours after addition of DOX using anti-VSV and anti-rabbit-IgG antibodies 
for ChIP. qChIP values are represented as percentage of input chromatin and qChIP amplicons 
are indicated. Error bars represent +/- SE (n=2). (C) ChIP assay in SW620 cells using an 
antibody against the endogenous ZNF281 protein. Results represent the mean +/- SD (n=3).  
In (B) and (C) ZNF281 occupancy at the indicated promoters or chromosomal region 16q22, 
which served as negative control, is shown. 
 
 
 
Figure 37: The ectopic expression of ZNF281 in DLD-1 cells increases the ability of the 
cells to form colono-spheres. DLD-1/pRTR-ZNF281-VSV cells were analyzed. (A) 
Representative phase-contrast images of spheres grown on low adherence plates seven days 
after addition of DOX. The scale bar represents 50 µm. (B) Quantification of the sphere number 
per 1000 cells. Results represent the mean +/- SD (n=3). A Student’s t-test was used. 
***: p<0.001. 
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5.1.7 Requirement of ZNF281 for EMT, migration and invasion 
   Next, it was thought to determine whether ZNF281 is not only sufficient for the 
induction of EMT, but also necessary for the maintenance of an EMT-like state in the 
CRC cell line SW480, which displays mesenchymal features such as low E-cadherin 
and high SNAIL expression (Figure 11) as well as enhanced migration, invasion and 
metastasis. In line with our previous findings SW480 cells displayed high levels of 
endogenous ZNF281 when compared to the more epithelial cell lines DLD-1 and HT29 
(Figure 11). Therefore, we generated SW480 cell pools with DOX-inducible expression 
of a ZNF281-specific-miRNA or the respective control driven by an episomal pRTS 
vector. These cell pools showed ectopic expression of an inducible, co-expressed 
mRFP marker in ~90% of the cells after addition of DOX (Figure 38).  
 
Figure 38: Determination of mRFP positivity of the cells used. Flow cytometric analysis of 
mRFP positivity 48 hours after addition of DOX. (A) and (B) SW480/pRTS-ZNF281-spec.-
miRNA #1/2 cells were analyzed. (C) Flow cytometric analysis of SW480/pRTS-non-spec.-
miRNA cells. 
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   After induction of the ZNF281-specific miRNAs endogenous ZNF281 was repressed 
at the mRNA and protein level (Figure 39A and B). Simultaneously, mesenchymal 
markers such as SNAIL and Vimentin were repressed, whereas E-cadherin as epithelial 
marker was induced at the protein level (Figure 39B). Furthermore, SW480 cells lost 
their mesenchymal morphology upon ZNF281 knock-down and gained epithelial 
phenotypes with an increase in cell-cell contacts (Figure 40) and diminished expression 
of Vimentin (Figure 39B and Figure 40). Moreover, down-regulation of ZNF281 in 
SW480 cells resulted in decreased migration in a scratch and a Boyden-chamber assay 
(Figure 41A and C and Figure 41B and D respectively) as well as diminished invasion in 
a Matrigel-transwell assay (Figure 41B and D). The down-regulation of ZNF281 in 
SW480 cells had no significant effect on cell proliferation, cell cycle distribution and 
apoptosis (Figure 42). In addition, ZNF281 down-regulation resulted in a decrease in 
colony formation in soft agar (Figure 43A) and a reduction in sphere formation 
(Figure 43B). Similar effects were observed after expression of the other ZNF281-
specific-miRNA (Figure 43C and D), whereas induction of a non-specific control miRNA 
did not result in significant effects in any of the assays described above (Figure 44A-D). 
Taken together, down-regulation of ZNF281 induces MET in SW480 cells, which is 
associated with the loss of migratory and invasive capacities as well as reduced 
stemness. Therefore, expression of ZNF281 is not only sufficient for the induction of 
EMT, but presumably required to maintain a mesenchymal state in colorectal cancer 
cell lines. Furthermore, ZNF281 is not only sufficient to induce SNAIL, but also 
necessary for its continued expression. 
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 Figure 39: miRNA-mediated repression of ZNF281. SW480 cells harboring a pRTS vector 
encoding a miRNA directed against endogenous ZNF281 (ZNF281-specific-miRNA (ZNF281-
spec.-miRNA#1/2)) or pRTS non-specific control miRNA (non-spec.-miRNA) were analyzed. 
(A) qPCR analysis of the ZNF281 mRNA expression 96 hours after addition of DOX. Results 
represent the mean +/- SD (n=3). (B) Western blot analysis of the indicated proteins 96 hours 
after addition of DOX. β-actin served as a loading control.  
 
 
 
Figure 40: miRNA-mediated repression of ZNF281 influences the cell morphology. SW480 
cells harboring a pRTS vector encoding a miRNA directed against endogenous ZNF281 
(ZNF281-specific-miRNA (ZNF281-spec.-miRNA#1/2)) or pRTS non-specific control miRNA 
(non-spec.-miRNA) were analyzed. Representative phase contrast pictures 96 hours after 
addition of DOX. 200 x magnification. Middle part: confocal microscopy to detect Vimentin 
protein by indirect immunofluorescence staining. Nuclear DNA was visualized by DAPI staining. 
200 x magnification. Scale bars represent 25 µm. 
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 Figure 41: Repression of ZNF281 diminishes the migratory and invasive capacities of 
SW480 cells. SW480 cells harboring a pRTS vector encoding a miRNA directed against 
endogenous ZNF281 (ZNF281-spec.-miRNA#1/2) were analyzed as indicated. (A) Wound 
healing assay: SW480/pRTS-ZNF281-spec.-miRNA#1 cells were treated with DOX or left 
untreated 72 hours prior to scratching. Representative pictures of the wounding areas are 
shown. 100 x magnification. Results represent the mean average (%) +/- SD of wound closure 
determined by the final width of the scratch in three independent wells (n=3). (B) Boyden-
chamber assay. Left panel: migration after treatment with DOX or left untreated for 72 hours, 
serum starvation for the last 48 hours and migration through the Boyden-chamber filter for 48 
hours. Right panel: invasion through a Matrigel-coated filter for 48 hours. Results represent the 
relative change of cells detected in five fields in the Boyden-chamber with untreated cells set as 
one +/- SD (n=3). (C) Wound healing assay: SW480/pRTS-ZNF281-spec.-miRNA#2 cells were 
treated with DOX or left untreated 72 hours prior to application of a scratch. Wound healing was 
monitored at 0 and 48 hours. Representative pictures of the wounding areas are shown (left 
panel). 100 x magnification. Right panel: results represent the mean percentage of the closed 
wound area +/- SD (n=3). (D) In a Boyden-chamber migration assay cells according to (C) were 
treated with DOX or left untreated for 72 hours with serum starvation for the last 48 hours and 
allowed to migrate through the filter for 48 hours. In a Boyden-chamber invasion assay the cells 
were allowed to invade through a Matrigel-coated filter for 48 hours. Results represent the mean 
with untreated cells set to one +/- SD (n=3). 
A Student’s t-test was used in (A-D). *: p<0.05, **: p<0.01 and ***: p<0.001. 
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 Figure 42: Repression of ZNF281 does not impact cell proliferation. SW480 cells harboring 
a bicistronic pRTS-ZNF281-specific-miRNA#1/2 or non-specific-miRNA vector were treated with 
DOX for the indicated periods to activate expression of the respective miRNA or left untreated. 
(A) Proliferation assay after addition of DOX for the indicated periods to activate the particular 
miRNAs. (B) Cell cycle analysis of the indicated cells 48 hours after addition of DOX. 
(C) Representative phase-contrast pictures of the indicated cells. Cells were grown in medium 
with 10% (+) or 0.1% (-) FCS as indicated. 200 x magnification, scale bar represents 50 µm. 
(D) Cells treated with DOX for 48 hours or left untreated in medium with 0.1% FCS (-FCS) were 
subjected to cell cycle analysis.  
In (A), (B) and (D) results represent the mean +/- SD (n=3).  
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 Figure 43: Down-regulation of ZNF281 via specific miRNAs influences colony and sphere 
formation. SW480 cells harboring a bicistronic pRTS-ZNF281-specific-miRNA#1/2 were 
treated with DOX for the indicated periods to activate expression of the respective miRNA or left 
untreated. (A and C) Cells were subjected to a soft-agar assay and treated with DOX or left 
untreated during the experiment. Three weeks after seeding the resulting colonies were stained 
with crystal violet. Results represent the mean number of colonies in soft agar per well +/- SD 
(n=3). (B and D) Quantification of colono-spheres formed. The results are provided as the mean 
number of spheres formed per 1000 cells seeded +/- SD (n=3). 
A Student’s t-test was used in (A-D). ***: p<0.001. 
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 Figure 44: Expression of a non-specific miRNA does not have any impact on SW480 
cells. SW480/pRTS-non-spec.-miRNA cells were analyzed. (A) Wound healing assay: the cells 
were treated with DOX or left untreated 72 hours prior to scratching. Wound healing was 
monitored immediately and 48 hours after scratching and representative pictures of the 
wounding areas are shown (left panel). 100 x magnification. Right panel: results represent the 
mean percentage of the closed wound area +/- SD (n=3). (B) In a Boyden-chamber migration 
assay the cells were treated with DOX or left untreated for 72 hours with serum starvation for 
the last 48 hours and allowed to migrate through the filter for 48 hours. In a Boyden-chamber 
invasion assay the cells were allowed to migrate through a Matrigel-coated filter for 48 hours. 
Results represent the mean with untreated cells set to one +/- SD (n=3). (C) The cells were 
subjected to a colony formation assay in soft-agar and treated with DOX or left untreated. Three 
weeks after seeding the resulting colonies were stained with crystal violet. Results are provided 
as the mean +/- SD (n=3). (D) Quantification of colono-spheres. The results are provided as the 
mean number of spheres formed per 1000 cells seeded +/- SD (n=3).  
In (A-D) a Student’s t-test was applied with p>0.05 being considered non-signiﬁcant (n.s.). 
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5.1.8 Requirement of ZNF281 for c-MYC-induced EMT 
   Recently, it has been observed that ectopic c-MYC expression effectively induces 
EMT in DLD-1 cells, which was accompanied by an activation of SNAIL expression 
mediated to a large extend by AP4 (Jackstadt et al, 2013). Since an interaction between 
c-MYC and ZNF281 had also been detected before (Koch et al, 2007), the question was 
addressed whether ZNF281 is required for c-MYC-induced EMT. c-MYC activation 
resulted in an induction of ZNF281 expression at the protein and mRNA level 
(Figure 45A and B). This was presumably indirect since MYC binding sites (E-boxes) 
were not identified in the ZNF281 promoter region. Interestingly, ectopic c-MYC 
expression and concomitant transfection of a SNAIL-specific siRNA diminished the 
induction of ZNF281 (Figure 46). When c-MYC was ectopically expressed in DLD-1 
cells in the presence of siRNAs directed against ZNF281, the repression of E-cadherin 
and also the induction of SNAIL was less pronounced than with co-transfection of a 
control siRNA (Figure 47A). In addition, siRNA-mediated down-regulation of ZNF281 
prevented the adoption of a mesenchymal phenotype after activation of c-MYC in 
colorectal DLD-1 cells (Figure 47B). After activation of ectopic c-MYC and concomitant 
transfection of the ZNF281-specific siRNAs E-cadherin remained at the membrane, 
whereas co-transfection of a control siRNA did not interfere with the c-MYC-induced 
loss of membranous E-cadherin (Figure 47B). Taken together, these results show that 
c-MYC-induced EMT is mediated by ZNF281. 
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 Figure 45: The expression of ZNF281 is induced by c-MYC. DLD-1/pRTR-c-MYC-VSV cells 
were analyzed. (A) Cells were treated with DOX for the indicated periods and subjected to 
Western blot analysis of the indicated proteins. Detection of β-actin served as loading control. 
(B) qPCR analyses of ZNF281 mRNA expression at the indicated time-points. Results represent 
mean values +/- SD (n=3). A Student’s t-test was used. *: p<0.05. The DLD-1/pRTR-c-MYC-
VSV cells were generated by Rene Jackstadt and further the respective cDNA samples were 
kindly provided by Rene Jackstadt. 
 
 
 
 
Figure 46: siRNA-mediated knock-down of SNAIL prevents the c-MYC-mediated 
induction of ZNF281. DLD-1/pRTR-c-MYC-VSV cells were transfected with the indicated 
siRNAs for 72 hours and DOX (indicated by +) was added for the last 24 hours. Subsequently, 
the indicated proteins were detected by Western blot analysis. Detection of β-actin served as 
loading control.  
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 Figure 47: siRNA-mediated knock-down of ZNF281 prevents the c-MYC-induced EMT. 
(A) DLD-1/pRTR-c-MYC-VSV cells were transfected with two different ZNF281-specific 
(ZNF281 #1 and ZNF281 #2) siRNAs or the respective control (ctrl.) for 96 hours. For the last 
24 hours DOX was added. Subsequently, the indicated proteins were detected by Western blot 
analysis. Detection of β-actin served as loading control. Relative densitometric quantifications 
are indicated. ZNF = ZNF281, E-cad = E-cadherin. (B) Representative phase-contrast (P/C) 
images of the cells analyzed in (A). 200 x magnification. Detection of E-cadherin was done by 
indirect immunofluorescence using confocal laser-scanning microscopy. Nuclear DNA was 
visualized by DAPI staining. 200 x magnification. siRNA control had no effect on these cells in 
the absence of DOX (lower panel). The scale bars represent 25 µm. 
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5.1.9 Role of ZNF281 in metastasis formation 
   Since EMT and the resulting cellular properties have been implicated in the metastatic 
process (Valastyan & Weinberg, 2011) it was asked whether inactivation of ZNF281 in 
the highly metastatic CRC cell line SW620 would influence metastases formation in a 
xenograph mouse model. Therefore, SW620 cells stably expressing luciferase2 were 
generated to monitor the development of metastases over time in a non-invasive 
manner (Figure 48A-C). Transfection of SW620-Luc2 cells with two different ZNF281-
specific siRNAs resulted in a pronounced down-regulation of ZNF281 expression, which 
was accompanied by a decrease in Vimentin and SNAIL protein (Figure 49) in line with 
SNAIL being a direct target gene of ZNF281 (Figure 26A and B).  
 
Figure 48: Characterization of SW620 Luc2 cells. Characterization of SW620 cells 
constitutively expressing Luc2 and tdTomato from a retroviral vector. (A) Flow cytometric 
detection of tdTomato expression of parental (black) and clone 1 (red) SW620 cells. 
(B) Measurement of the luciferase activity in the indicated cells 30 minutes after the addition of 
D-luciferin (150 µg/ml final concentration). (C) Cell proliferation was determined by impedance 
measurement in medium containing 10% serum. The cell index generally corresponded to the 
relative cell number.  
These analyses were performed by Rene Jackstadt. The figure was also generated by Rene 
Jackstadt. 
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 Figure 49: siRNA-mediated repression of ZNF281 results in decreased SNAIL and 
Vimentin protein expression. SW620 cells stably expressing a pLXSN-Luc2-tdTomato vector 
were transfected with the respective siRNAs. After 72 hours Western blot analysis was 
performed to detect the indicated proteins. Detection of β-actin served as a loading control.  
The cell lysates were provided by Rene Jackstadt.  
 
   Subsequently, these cells were injected into the tail vein of NOD/SCID mice. Within 
four weeks mice injected with control siRNA transfected cells gave rise to luminescence 
signals in the lung indicating metastases, whereas mice injected with cells transfected 
with ZNF281-specific siRNAs did not show luminescence signals until seven to eight 
weeks after injection (Figure 50). Nine weeks after injection luminescent metastases 
were easily detectable in mice, which had received control siRNA treated cells, whereas 
cells treated with ZNF281-specific siRNAs only rarely gave rise to small metastases as 
evidenced by weak luminescence signals (Figure 50 and 51A). At this time-point lungs 
displayed macroscopically visible metastases in the control group, while lungs from 
mice injected with cells transfected with ZNF281-specific siRNAs were devoid of 
macroscopically visible metastases (Figure 51A). Haematoxylin and eosin (H&E) 
staining revealed the presence of metastases in the lungs of the control siRNA group, 
whereas the knock-down of ZNF281 largely prevented the colonization of SW620 cells 
in the lung (Figure 51A). Histological examination of the lungs revealed a significant 
decrease in the total number of metastatic nodules upon inhibition of ZNF281 
(Figure 51B). In conclusion, ZNF281 is necessary for metastatic colonization of CRC 
cells in this in vivo model. 
87
?????????????????????????????????????????????????????????????????????????????????????????
????????????? ?????????????????????????????????????????????????????????????????? ???????????
??????????????????????????????????????????????????????????????????????????????? ?????????????????
????????? ?????????????????????????????????????????????????????????????? ??????????
???????????????????????????? ?????????????????????????????????? ??????????????????????
???????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
???????????
?
?
??????? ??????????? ??????????? ??? ????????? ???? ???? ???????????? ??? ????? ??????????? ???
??????????????????? ?????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????? ????????????????????????????????????????????????
???????????????? ???????????????????????????????????????????????????????????????????????????
?????? ???? ????????????? ?????????? ??? ???? ?? ??? ???????????? ?????? ??????? ??????? ???????
??????????????? ????????? ??? ???? ????????? ?????? ???? ??????? ???? ?????? ?????????? ??
??????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????? ??????????????????????????
?????????????????????????????????????????????????????????????????? ??? ???? ????????????????????
??????????????????????????????????????????????????????????????????????????????????????? ?????????
??????????????????? ???????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????? ??????????????????????????????????
???????????
88
5.1.10 ZNF281 is up-regulated in human colon and breast cancer 
   In order to evaluate whether the pro-metastatic functions of ZNF281 are reflected in 
enhanced expression of ZNF281 during progression of CRC and other carcinomas the 
Oncomine database was used for analyses (Rhodes et al, 2004). In eleven out of 
twelve tumor entities ZNF281 expression was found to be up-regulated in tumor versus 
normal tissue (Figure 52). In primary tumor samples of two colorectal and two breast 
cancer cohorts cancer-specific up-regulation of ZNF281 was consistently found (Figure 
53A-D). In addition, an increased ZNF281 expression in the primary tumor of colorectal 
cancer patients was associated with recurrence, and therefore presumably metastasis, 
three years after removal of the primary tumor (Figure 53E). 
 
 
Figure 52: Comparison of ZNF281 expression levels in multiple human cancers. Analysis 
of ZNF281 mRNA expression in human Oncomine datasets (datasets updated as of November 
2011). Summary of ZNF281 mRNA expression in various human cancer types compared to the 
respective normal tissue. Indications of the colors used: red: up-regulated in cancer; blue: 
down-regulated in cancer. 
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6. DISCUSSION 
  The results obtained in this thesis show that ZNF281 is an integral part of the 
regulatory network controlling the transition between epithelial and mesenchymal states 
in colorectal cancer cells (see schematic model in Figure 54). The results further 
demonstrate a coherent feed-forward loop consisting of SNAIL and miR-34a which 
induces ZNF281 expression. Furthermore, the sufficiency of ZNF281 expression for 
induction of EMT and its requirement to maintain a mesenchymal state in CRC cell lines 
was shown. This effect is mediated by the direct activation of SNAIL and repression of 
epithelial marker genes and effectors. Additionally, it could be shown that ZNF281 
regulates stemness. By these mechanisms ZNF281 presumably contributes to 
metastases formation. 
 
 
Figure 54: ZNF281 as a regulator of EMT and stemness. Schematic model integrating the 
results of this study with previous findings. Green rectangles represent factors that promote and 
red rectangles represent factors that inhibit EMT and stemness. EMT in combination with 
increased cancer cell stemness promotes the formation of metastases (Hahn et al, 2013). 
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   As depicted in Figure 54, a coherent feed-forward loop involving the EMT-TF SNAIL 
regulates ZNF281 expression in CRC cells, where SNAIL directly binds to the ZNF281 
promoter and induces its transcription. Although SNAIL is mainly known as a 
transcriptional repressor direct induction of target genes by SNAIL has been shown (De 
Craene et al, 2005; Guaita et al, 2002; Rembold et al, 2014; Vetter et al, 2010). This 
regulatory loop also involves miR-34a, which in turn is repressed by SNAIL in a 
negative feedback loop (Kim et al, 2011; Siemens et al, 2011) and itself could be shown 
to target ZNF281. Additional evidence could be provided that ZNF281 is induced by 
SNAIL also in other types of carcinomas such as pancreatic and breast carcinomas. 
Furthermore, miR-34a repressed ZNF281 in a pancreatic cancer cell line. Therefore, 
the regulations described here may also be important for the regulation of EMT and 
metastasis in other types of carcinomas besides CRC. Recently, increased SNAIL 
expression was demonstrated to inversely correlate with miR-34a expression in a 
cohort of 94 colon cancer patients and associate with liver metastasis (Siemens et al, 
2013). Therefore, the increased expression of ZNF281 identified in public datasets of 
colorectal and other tumor types may be caused by down-regulation of miR-34a 
expression due to cancer-specific CpG methylation and/or p53 inactivation. Ectopic 
ZNF281 expression directly induced SNAIL transcription. However, this resulted in 
varying degrees of EMT effector regulations in the two different CRC cell lines DLD-1 
and HT29, especially with regard to the effects on CDH-1 mRNA. In DLD-1 cells rather 
the E-cadherin protein expression was decreased upon ectopic ZNF281 expression, but 
not the CDH-1 mRNA expression level. In contrast, in the colorectal cell line HT29 the 
E-cadherin/CDH-1 was negatively regulated on transcriptional and protein level, 
displaying cell type specific differences with regard to the transcriptional influence on 
CDH-1. This raises the question as to whether loss of CDH-1 is necessary for the loss 
of cellular adhesions. Indeed, in human breast cancer cells loss of E-cadherin 
expression is not required for EMT (Hollestelle et al, 2013) as some breast cancer cell 
lines gained a spindle like cell morphology and revealed increased mesenchymal 
markers, but failed to repress E-cadherin expression during induction of EMT. Further, it 
has been shown that E-cadherin reconstitution in E-cadherin negative cell lines that had 
undergone EMT failed to revert the mesenchymal phenotype back to an epithelial 
phenotype (Hollestelle et al, 2013). This may indicate cell type-specific differences in 
various colorectal cancer cell lines during EMT and E-cadherin regulation. Nonetheless, 
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ZNF281 expression consistently resulted in the loss of intercellular adhesions and 
enhanced migration and invasion in HT29 and DLD-1 CRC cells. The subtle differences 
in the transcriptional response of different CRC cell lines to ZNF281 activation may be 
due to variations in related signaling pathways and therefore varying degrees of 
permissiveness for EMT or plasticity of the respective cells. Moreover, a number of 
additional epithelial marker genes encoding components of tight junctions (ZO-1/3, 
CLDN-1) and adherens junctions (CDH-3) as well as desmosomes (PKP2, DSP) were 
repressed upon ectopic expression of ZNF281 in DLD-1 cells, which may further 
contribute to the loss of cell-cell contacts, as previously shown for ZEB2 (Vandewalle et 
al, 2005). The ZNF281 paralog ZBP89 has been demonstrated to repress the 
mesenchymal marker Vimentin via the interaction with Sp1 in Drosophila Schneider 
cells (S2) (Zhang et al, 2003). Moreover, a similar repressive effect of ZNF281 on a 
Vimentin minimal promoter reporter has been shown in S2 cells (Zhang et al, 2003). In 
contrast, evidence has been provided here that in human CRC cells Vimentin 
expression is enhanced upon ectopic ZNF281 expression, whereas knock-down of 
ZNF281 resulted in a repression of Vimentin. Presumably, species-specific differences 
might account for these different observations as well as variations in the experimental 
settings. For example artificial protein-protein-interactions in the minimal promoter 
reporter system might occur compared to the natural settings of the investigation of 
endogenous expression levels. Nevertheless, further experiments might reveal more 
similarities and differences between the two paralogs since the homology primarily 
concerns the zinc finger regions whereas several other domains differ as e.g. the acidic 
domain, which is not present in ZNF281 and might be responsible for ZBP-89 mediated 
protein-protein-interactions (Lisowsky et al, 1999). The results demonstrate that 
ZNF281 represents a new EMT-promoting transcription factor. Notably, ZNF281 is 
structurally related to the zinc-finger transcription factor family like SNAIL, SLUG and 
ZEB1/2 (as indicated in Figure 55). However, there is a major difference between 
ZNF281 and the core EMT-transcription factors (EMT-TFs) SNAIL, SLUG and ZEB 
concerning the recognition site in target promoters. Whereas the above mentioned core 
EMT-TFs bind to a non-canonical E-Box motif (CACCTG), ZNF281 so far just has been 
shown to bind to GC-rich regions in the promoter of e.g. ODC (Law et al, 1999; 
Lisowsky et al, 1999). This might lead to differences in the set of genes being regulated 
during the process of EMT and requires further investigation in order to understand the 
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role of ZNF281 in this process. Moreover, additional information should be gained on 
ZNF281 and the specificity, redundancy and/or cooperation within the network of EMT-
inducing factors. Furthermore, it might be possible that ZNF281 can actively be 
recruited to specific promoters as a co-factor. Alternatively, direct functional interactions 
with other EMT-TFs are possible.  
 
 
 
Figure 55: Comparison of ZNF281/ZBP-99, ZBP-89 and other EMT-inducing transcription 
factors (EMT-TFs). Numbers represent amino acids (aa). Colored boxes represent the 
indicated domains (Hahn & Hermeking, 2014, revised version submitted). 
 
   It is well documented that EMT is regulated by several regulatory networks (as 
described in chapter 1.3.1.1), presumably to confer robustness to the process. The 
most prominent network is built by the core EMT-transcription factors SNAIL, SLUG, 
ZEB and TWIST. However, there are additional networks existing in parallel. miRNAs, 
differential splicing and translational and post-translational control represent additional 
regulatory layers (De Craene & Berx, 2013). ZNF281 was integrated within some of 
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those regulatory networks due to the feed-forward regulation by SNAIL and miR-34a. 
Since miR-34a/b/c genes are directly repressed by SNAIL (Siemens et al, 2011), the 
induction of ZNF281 by SNAIL represents a feed-forward regulation, which is mediated 
by at least two mechanisms: transcriptional activation of ZNF281 and suppression of a 
ZNF281-specific miRNA. Therefore, it seems to be worth to further investigate other 
potential aspects of ZNF281-mediated EMT regulation with regard to post-translational 
events or the possible impact of ZNF281 on the chromatin structure of certain EMT-
relevant genes with regard to the induction and maintenance of an EMT. Epigenetic 
changes play an important role for the regulation of EMT (Tam & Weinberg, 2013) and 
the epigenetic regulation of the CDH-1 promoter represents the most extensively 
studied example. SNAIL expression has been associated with CDH-1 promoter 
methylation by introducing repressive histone modifications through the recruitment of 
the histone deacetylases 1/2 (HDAC 1/2) (Peinado et al, 2004). Furthermore, SNAIL 
may recruit histone modifying enzymes such as the demethylase LSD1, the 
methyltransferases EZH2, SUZ12, SUV39H1 as well as G9a to the promoters of its 
target genes (Dong et al, 2013; Dong et al, 2012; Herranz et al, 2008; Lin et al, 2010). 
Also ZEB1 has been shown to modify the histone marks of histone H3 at the CDH-1 
promoter via recruitment of the sirtuin1 (SIRT1) deacetylase resulting in a diminished 
binding capacity of RNA polymerase II (Byles et al, 2012). Since genome-wide 
epigenetic reprogramming is involved in EMT (Tam & Weinberg, 2013) it is necessary 
to carry out further studies on how ZNF281 might influence genome-wide changes in 
gene expression by interacting with different epigenetic modifiers as shown for other 
EMT-transcription factors. The current literature further suggests an extensive crosstalk 
between EMT-inducing transcription factors and miRNAs during the establishment and 
maintenance of the mesenchymal phenotype of cells (reviewed in (De Craene & Berx, 
2013; Sanchez-Tillo et al, 2012)). The list of directly or indirectly EMT-influencing 
miRNAs increased extensively during the past years. However, mainly two miRNA 
families are associated with EMT: the miR-200 and miR-34 families (De Craene & Berx, 
2013; Lu et al, 2013a; Tian et al, 2013). Interestingly, both miRNA families are under 
the positive control of the tumor suppressor p53 (Chang et al, 2011; Hermeking, 2012; 
Siemens et al, 2011). The miR-34 family has an impact on the regulation of the EMT-
process towards epithelial differentiation by directly controlling SNAIL and ZEB 
expression (Kim et al, 2011; Siemens et al, 2011). The presented results now further 
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extend this network by adding reciprocal connections between SNAIL, ZNF281 and 
miR-34a. Epithelial differentiation further has been associated with the expression of the 
miR-200 family. Both EMT and MET are tightly controlled via a reciprocal feedback loop 
consisting of the miR-200 family and ZEB1/2 (Gregory et al, 2008; Korpal et al, 2008; 
Park et al, 2008). Besides targeting ZEB1/2 miR-200 further mediates differentiation by 
down-regulation of epigenetic modifiers such as BMI1 and SUZ12 (Iliopoulos et al, 
2010; Wellner et al, 2009). The epithelial and mesenchymal phenotypes of cells as well 
as cells with mixed characteristics seem to be regulated by an interconnected circuit 
consisting of the miR-34/SNAIL and the miR-200/ZEB1/2 mutual-inhibition feedback 
circuits (Lu et al, 2013a). Lu et.al tested modeled predictions of dynamic gene 
expression to closer define changes in gene expression during complete and partial 
epithelial and mesenchymal transitions with regard to the miR-34/SNAIL and the miR-
200/ZEB1/2 circuits. They proposed that the miR-200/ZEB1/2 loop acts as ternary 
switch between epithelial, mesenchymal and hybrid phenotypes, which is driven by 
miR-34/SNAIL as integrator of internal and external signals (Lu et al, 2013a). Besides 
SNAIL and ZEB1/2, which are targeted by miR-34 and miR-200 respectively, it was 
recently shown that the c-MYC-induced EMT-TF AP4 is negatively regulated by miR-
15a/16-1 (Shi et al, 2014). Therefore, multiple axes of mutual miRNA and EMT-TF 
regulations mediate the suppression of the mesenchymal state by p53, which ultimately 
leads to inhibition of invasion, stemness and metastasis (Figure 56). Thereby, p53 may 
achieve a more effective and robust tumor suppression, which is presumably more 
resistant to the loss of single down-stream components than a single linear signaling 
pathway would be. 
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Figure 56: The regulation of EMT/MET by miRNAs and EMT-TFs. Model summarizing the 
regulatory loops connecting p53-induced MET-promoting miRNAs (beige) and EMT-TFs (green) 
(Hahn & Hermeking, 2014, revised version submitted). 
 
     The opposite mode of regulation of ZNF281 by SNAIL and miR-34a already implies 
that the correct concentration of ZNF281 is important for the regulation of EMT. In order 
to disseminate from the tumor mass and to intravasate into and extravasate from the 
bloodstream tumor cells have to undergo EMT. They gain a mesenchymal phenotype 
along with the capacities to migrate, invade and survive in adverse environments. 
Nevertheless, cancer cells in the invasion-metastasis-cascade are further dependent on 
the reverse program of MET in order to restart proliferation after settling down in distant 
organs (Nieto, 2013). The reversibility of epithelial and mesenchymal phenotypic 
changes is important for cancer cells in order to form micro- and macro-metastases 
(Scheel & Weinberg, 2012; Thiery, 2002; Thiery et al, 2009). Expression of EMT-
inducing factors such as SNAIL resulted in diminished proliferation (Peinado et al, 2007) 
being counterproductive for the outgrowth of a metastasis. It has been shown that 
carcinoma metastases adopt a differentiated epithelial phenotype resembling the 
pathological histology of the primary tumor (Brabletz et al, 2001). This reflects the 
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epithelial plasticity implicated in tumor progression and the importance of MET. The 
repression of ZNF281 by miR-34a may be part of the MET-process and experimental 
down-regulation of ZNF281 resulted in an epithelial phenotype. These findings integrate 
the new EMT-TF ZNF281 in the regulatory system including EMT-TFs and MET-
promoting miRNAs. Therefore, in vivo mechanisms down-regulating ZNF281 at distant 
sites are an interesting object for future analyses. 
   Previously, it has been shown that c-MYC binds to ZNF281 (Koch et al, 2007). Here, 
it has been found that ectopic expression of c-MYC increased ZNF281 expression. The 
absence of c-MYC binding sites in the promoter region of ZNF281 implies the existence 
of alternative regulatory mechanisms. Here, it was shown that c-MYC-mediated 
induction of SNAIL led to the enhanced expression of ZNF281. In addition, c-MYC has 
been shown to directly down-regulate miR-34a in human and mouse B cell lymphoma 
models, which contributes to tumorigenesis (Chang et al, 2008). However, c-MYC-
induced SNAIL could additionally repress miR-34, which would further contribute to 
increased ZNF281 expression. Alternatively, the association of c-MYC protein with 
ZNF281 may inhibit the turn-over of ZNF281. Moreover, ZNF281 represents a 
necessary mediator of SNAIL- and c-MYC-induced EMT. Therefore, ZNF281 might be 
an important mediator of tumor progression in tumor entities with deregulation of the 
oncoprotein c-MYC. EMT-TFs are known to regulate each other (Hugo et al, 2011; 
Taube et al, 2010). It could be demonstrated that in different cell lines with concomitant 
expression of multiple EMT-inducers the knock-down of even a single EMT-TF was 
sufficient enough to partially or completely block EMT and metastases formation (Casas 
et al, 2011; Olmeda et al, 2008; Spaderna et al, 2008). Recently, core microRNA- as 
well as core gene-signatures associated with various inducers of EMT were defined 
(Diaz-Martin et al, 2014; Hugo et al, 2011; Moreno-Bueno et al, 2006; Taube et al, 
2010). Nevertheless, additional EMT-TF-specific alterations of the regulated genetic 
programs were shown, which support also differential roles of the different EMT-TFs for 
tumor progression and invasion (Diaz-Martin et al, 2014; Hugo et al, 2011; Moreno-
Bueno et al, 2006; Taube et al, 2010). Therefore, it seems to be necessary to determine 
the similarities and differences of ZNF281-induced EMT compared to EMT induced by 
other EMT-inducing factors as well as the mode of interaction within the EMT network. 
   It has been shown before that the EMT process yields cells with properties of stem 
cells (Polyak & Weinberg, 2009; Valastyan & Weinberg, 2011). For example, activation 
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of the EMT-inducers SNAIL and ZEB1 promotes the formation of tumor initiating cells 
with stem cell properties (Dang et al, 2011; Hwang et al, 2011; Mani et al, 2008; Wellner 
et al, 2009). Recently, an enrichment of ZNF281 has been demonstrated in basal 
epidermal stem cells (Yi et al, 2008), which suggests a stemness-related function of 
ZNF281. In addition, a chromatin immunoprecipitation (ChIP) analysis of mouse 
embryonic stem cells (ESCs) ectopically expressing ZNF281 revealed more than 2,000 
direct ZNF281 targets including several known regulators of pluripotency (Wang et al, 
2008). Additionally, global analysis of gene expression after knock-down of ZNF281 in 
murine cells revealed numerous activated and repressed genes indicating a bifunctional 
role of ZNF281 within diverse molecular networks (Wang et al, 2008). Moreover, 
ZNF281 seems to be involved in the regulation of pluripotency by interacting with the 
core transcriptional regulatory network factors controlling stemness, including NANOG, 
OCT4 and SOX2 (Wang et al, 2006; Wang et al, 2008). Notably, ZNF281 was also 
shown to bind to c-MYC (Koch et al, 2007), another factor implicated in the regulation of 
pluripotency and induced pluripotent stem cell (iPSC) formation. RNA-interference 
mediated down-regulation of ZNF281 in murine ESC clones led to the differentiation of 
ESCs, whereas enforced ZNF281 expression resulted in the suppression of ESC 
differentiation, which occurs after LIF deprivation (Wang et al, 2006; Wang et al, 2008). 
Taken together, these results show that appropriate expression of ZNF281 is not only 
required for the maintenance of pluripotency, but also that its repression is necessary 
for induction of differentiation. However, in another study ZNF281 expression seemed 
to be dispensable for survival and proliferation of ESCs (Fidalgo et al, 2011). Moreover, 
ESCs with deletion of ZNF281 displayed a slightly enhanced self-renewal capacity 
(Fidalgo et al, 2011). Additionally, it has been shown that the depletion of ZNF281 
enhances the reprogramming of pre-induced pluripotent stem cells (pre-iPSCs) to 
iPSCs (Fidalgo et al, 2012). Several studies demonstrated that ZNF281 directly 
regulates NANOG expression in concert with OCT4 and SOX2 (Fidalgo et al, 2012; 
Fidalgo et al, 2011; Wang et al, 2008). ZNF281 recruits the NuRD repressor complex to 
the NANOG locus and contributes to the NANOG auto-regulation in mouse ESCs 
(Fidalgo et al, 2012; Fidalgo et al, 2011). Interestingly, Wang and colleagues identified 
potential binding sites for NANOG, SOX2 and OCT4 in the ZNF281 locus (Wang et al, 
2008), which implies the existence of regulatory feedback loops. In Medaka fish 
ZNF281 is preferentially expressed in gonads similar to SALL4, another pluripotency 
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factor (Wang et al, 2011). Additionally, elevated ZNF281 expression was shown during 
early embryonic development due to maternally supplied mRNA followed by a dramatic 
decrease during gastrulation (Wang et al, 2011). Notably, the elevated expression of 
ZNF281 in pluripotent cells is conserved between mammals and lower vertebrates 
(Wang et al, 2011). A growing body of evidence indicates that cancer stem cells exhibit 
characteristics similar to embryonic stem cells, since these often express genes, which 
are typically expressed in normal stem cells. As indicated above ZNF281 seems to be 
involved in the regulation of pluripotency and stemness by interacting with NANOG, 
OCT4 and SOX2 (Wang et al, 2006; Wang et al, 2008). Elevated expression of the 
pluripotency factors NANOG, OCT4 and SOX2 has been implicated in gastric, 
colorectal, lung, prostate, bladder, esophageal and breast cancer (Amsterdam et al, 
2013; Bornschein et al, 2013; Chen et al, 2012; Ibrahim et al, 2012; Lengerke et al, 
2011; Lu et al, 2013b; Lu et al, 2010; Raghoebir et al, 2012; Tsukamoto et al, 2005; 
Yasuda et al, 2011; Zhang et al, 2013; Zhang et al, 2010). Moreover, enhanced 
NANOG, OCT4 and SOX2 expression is associated with elevated tumorigenic potential 
(Chen et al, 2012; Chen et al, 2009; Ibrahim et al, 2012; Lu et al, 2013b; Xiang et al, 
2011) and metastases formation (Han et al, 2012; Liu et al, 2013; Lu et al, 2013b; Meng 
et al, 2010; Noh et al, 2012; Zhang et al, 2013). Furthermore, NANOG, OCT4 and 
SOX2 correlated with the differentiation status of tumors (Amsterdam et al, 2013; Chen 
et al, 2009; Liu et al, 2013; Raghoebir et al, 2012) and NANOG and OCT4 correlated 
with poor patient prognosis (Li et al, 2012; Matsuoka et al, 2012; Meng et al, 2010). 
Furthermore, down-regulation of SOX2 in breast cancer cells inhibited tumor growth in a 
mouse model (Stolzenburg et al, 2012). Over-expression of OCT4 has been detected in 
CRC samples and the induced pluripotent stem cell (iPS cell) signature (OCT4, NANOG 
and LIN28) correlated with tumor site, lymph node status and Dukes classification of 
CRC patients (Liu et al, 2013). Liu et al. further demonstrated increased sphere 
formation, proliferation, colony formation, migration and tumor growth of CRC cells upon 
mixed iPS gene expression consisting of the factors SOX2, c-MYC, OCT4 and KLF4 
(Liu et al, 2013), whereas the underlying mechanism lacks explanation and might point 
towards the influence of ZNF281 in cell colony formation and migration. Recent studies 
demonstrated that pluripotent stem cells derived from differentiated somatic cells (iPS 
cells) display similar properties as ESCs (Takahashi & Yamanaka, 2006). The 
generation of those iPS cells can be achieved by retroviral transduction of the four 
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transcription factors OCT4, SOX2, KLF4 and c-MYC (reviewed in (Yamanaka & Blau, 
2010)). Since ZNF281 interacts with the oncoprotein c-MYC (Koch et al, 2007) and has 
been shown to influence OCT4 and SOX2 (Wang et al, 2006; Wang et al, 2008), three 
out of four of the so called “Yamanaka” factors (Yamanaka & Blau, 2010) are 
functionally connected to ZNF281. However, so far it is unclear how important ZNF281 
is for the generation of the iPS cells. Due to the interaction of ZNF281 with NANOG, 
OCT4 and SOX2 and the enhanced expression of ZNF281 in breast and colorectal 
cancer it is conceivable that ZNF281 also contributes to the activity of NANOG, OCT4 
and SOX2 in tumors. However, whether this is the case may be the subject of future 
studies. Recently, a bimodal switch consisting of miR-34a and its target Notch1, which 
determines whether colorectal cancer stem cells (CCSCs) undergo symmetric or 
asymmetric divisions and therefore whether CCSCs differentiate, has been described 
(Bu et al, 2013). Decreased miR-34a and increased Notch1 expression are hallmarks of 
CCSCs, whereas the reverse expression pattern is found in differentiated cells. It 
seems to be likely that ZNF281, which was recently identified as a direct target of miR-
34a (Hahn et al, 2013), may also play a role in the miR-34a-mediated fate determination 
and suppression of stemness. In line with this assumption, ZNF281 is a direct target of 
miR-203 (Yi et al, 2008), which is known to suppress stem cell associated traits. 
ZNF281 expression was down-regulated in transgenic K14-miR-203 mice as well as in 
miR-203 transduced primary mouse keratinocytes (Yi et al, 2008). The miR-203 gene is 
repressed by the EMT-TF ZEB1 (Wellner et al, 2009) and its epigenetic silencing is 
required for EMT and various other properties of cancer stem cells (Taube et al, 2013). 
Furthermore, miR-203 and SNAIL form a double negative feedback loop (Moes et al, 
2012). Therefore, it is likely that SNAIL concomitantly with miR-203 form another feed-
forward ZNF281-regulating circuit similar to the newly identified SNAIL and miR-34a 
feed-forward regulation presented in this thesis.  
   Moreover, the ZNF281-induced re-localization of β-catenin to the nucleus and the 
concomitant enhancement of β-catenin activity might contribute to ZNF281-mediated 
stemness, since WNT signaling is necessary to maintain stem cells in the intestinal 
crypts (Brabletz et al, 2005b; Pinto & Clevers, 2005; Scoville et al, 2008). Interestingly, 
Seo et al. found that knock-down of ZNF281 resulted in decreased proliferation and 
diminished β-catenin expression in human multipotent stem cells (hMSCs) (Seo et al, 
2013). Conversely, ectopic ZNF281 expression led to increased β-catenin expression, 
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which was accompanied by direct binding of ZNF281 to the β-catenin promoter (Seo et 
al, 2013). The occupation of the β-catenin promoter by ZNF281 may also contribute to 
the enhanced expression of β-catenin that was observed after ectopic ZNF281 
expression in colorectal cancer cells (Hahn et al, 2013). Moreover, the study by Seo et 
al. showed that ZNF281 knock-down in umbilical cord blood-derived mesenchymal stem 
cells (hUCB-MSCs) inhibits the adipogenic differentiation ability probably due to the 
resulting decrease in β-catenin, an important factor for early events in the adipogenesis 
of MSCs (Seo et al, 2013). In contrast, the osteogenic potential of hUCB-MSCs was 
enhanced after ZNF281 knock-down (Seo et al, 2013). The latter was verified by 
subcutaneous implantation of hUCB-MSCs with silenced ZNF281 into mice, where the 
ZNF281-depleted hUCB-MSCs converted into osteoblasts more rapidly than the control 
cells (Seo et al, 2013). Furthermore, here it was demonstrated that ZNF281 directly 
represses Axin2, a negative regulator of the WNT pathway (Lustig et al, 2002). 
Thereby, ZNF281 presumably interrupts the negative feedback regulation of β-catenin 
by Axin2 and allows β-catenin to accumulate in the nucleus and activate target genes. 
However, ZNF281 might also promote β-catenin/TCF4 activity by mediating the loss of 
E-cadherin expression. E-cadherin is capable to prevent the nuclear localization and 
therefore activation of β-catenin by recruiting it to the cell-membrane (Orsulic et al, 
1999; Sadot et al, 1998). Here, it could be further demonstrated that ZNF281 induces 
the expression of the stem cell markers CD133 and LGR5. Additionally, ectopic ZNF281 
expression increased sphere formation of colorectal cancer cells, which is an indicator 
of stemness, whereas ZNF281 knock-down decreased sphere formation (Hahn et al, 
2013). Therefore, ZNF281 seems to be a regulator of tumor cell stemness similar to 
SNAIL, TWIST and ZEB1 which mediate increased stemness as well as EMT (Mani et 
al, 2008; Wellner et al, 2009). Colon tumors were shown to contain a subpopulation of 
CD133-positive cells with the ability to initiate tumor growth (Horst et al, 2008). In 
addition, high CD133 expression was associated with poor survival of colorectal cancer 
patients. Moreover, the combination of CD133 and the nuclear localization of β-catenin 
identified cases of low stage colorectal cancer with a high risk for tumor progression 
(Horst et al, 2009). In the future, the localization of ZNF281 in diverse stem cell 
compartments besides basal epidermal cells (Yi et al, 2008) has to be defined with 
respect to co-expression with stem cell markers and the expression pattern of other 
EMT-TFs. The expression of SNAIL und SLUG has already been observed in several 
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stem cell compartments such as those of melanocytes, hematopoietic cells as well as in 
the epithelial compartment of the gut (Horvay et al, 2011; Perez-Losada et al, 2002; 
Sanchez-Martin et al, 2003).  
   Since down-regulation of ZNF281 prevented the formation of lung metastases of a 
CRC cell line in a xenograft mouse model, it seems likely that enhancement of EMT 
and/or stemness by ZNF281 are important functions of ZNF281 during CRC 
progression. The inhibition of metastases formation after experimental down-regulation 
of SNAIL has been observed in a similar assay (Jackstadt et al, 2013). Therefore, the 
effect of ZNF281 down-regulation might be mediated, at least in part, by decreased 
expression of SNAIL and the concomitant loss of mesenchymal properties. 
Furthermore, the down-regulation of ZNF281 by p53 via miR-34a indicates that limiting 
ZNF281 function is critical for tumor suppression by p53. The increased expression of 
ZNF281 mRNA in primary colorectal and breast carcinomas also points towards cancer 
promoting effects of ZNF281. Enhanced ZNF281 expression correlated with recurrence 
three years after removal of the primary colorectal tumor, suggesting that detection of 
elevated ZNF281 expression in primary tumors may have prognostic value. The 
ZNF281 paralog ZBP-89 already has been demonstrated to be up-regulated in various 
tumors such as gastric, colorectal and breast cancer (Zhang et al, 2012a). Moreover, 
enhanced ZBP-89 expression has been shown to correlate with the increased formation 
of distant metastases and poor survival of clear cell renal cell cancer patients (Cai et al, 
2012). This underlines the necessity of closer investigations of ZNF281 expression 
levels in tumor tissues besides colon and breast cancer. In normal tissue enhanced 
ZNF281 expression levels were detected in the placenta, kidney, brain, heart, liver and 
lymphocytes (Law et al, 1999). Moreover, the detection of ZNF281 for the clinical 
characterization of tumor samples seems to be important to define the clinical patient 
outcome and the probability for recurrence. 
   More efforts are necessary to identify new upstream regulators of ZNF281 to better 
incorporate the newly defined EMT-inducer ZNF281 into the existing network of EMT-
inducing transcription factors particularly with regard to potential regulatory signaling 
pathways. It should be interrogated whether well-known EMT-triggering pathways such 
as TGF-ß, WNT/β-catenin or HIF-1α signaling affect ZNF281 expression in order to 
induce EMT. Therefore, it seems to be important to precisely understand the role of 
ZNF281 within this process and to clearly define how ZNF281 and associated control 
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mechanisms influence tumor progression. The observations that systemic knock-out of 
ZNF281 is embryonically lethal (Fidalgo et al, 2011) and that EMT plays a major role in 
embryonic development emphasize the importance of further studies on ZNF281. 
Similar to the deletion of ZNF281, the germ-line deletion of the EMT-TF SNAIL resulted 
in early embryonic lethality around day E8 due to gastrulation defects (Carver et al, 
2001). To circumvent embryonic lethality Murray et al. generated mice with a floxed 
SNAIL allele, which allows the temporally controlled, Cre-mediated deletion of SNAIL 
and thereby the functional analysis of SNAIL in late embryogenesis and adult mice 
(Murray et al, 2006). Since systemic knock-out of ZNF281 is embryonically lethal this 
implies that organismal studies on ZNF281 using conditional, somatic knock-out 
strategies should be performed in order to determine the in vivo relevance of ZNF281 
during later stages of embryogenesis and postnatal development as well as in tumor 
progression and metastasis in more detail. 
   Tumor-suppressive miRNAs represent an interesting starting point for new 
therapeutical investigations with regard to cancer therapy as they are often down-
regulated during cancer progression. The repression of ZNF281 by miR-34a may be an 
important component of the MET-process and experimental down-regulation of ZNF281 
in a mesenchymal CRC cell line resulted in an epithelial phenotype. miR-34a might 
represent an attractive therapeutic starting point for ZNF281-mediated carcinogenesis. 
Kasinski and Slack demonstrated the therapeutic importance of miR-34a treatment by 
analyzing a Kras (LSL-G12D) (-/+) – Trp53 (LSL-R172H) (-/+) mouse lung cancer 
model. In vivo treatment by lentiviral infection with miR-34a prevented tumor formation 
and progression in those mice (Kasinski & Slack, 2012). This indicates the potential of 
miR-34 as a lung tumor-preventative and tumor–static agent (Kasinski & Slack, 2012), 
supposedly working via inhibition of SNAIL and ZNF281 as well as other miR-34a 
targets. Hence, a combined analysis of the status of miR-34a methylation, EMT-inducer 
expression (potentially ZNF281) and the following treatment with miR-34a mimicking 
molecules could represent a potential diagnostic and therapeutic approach in the clinic. 
Specific miRNA-replacement therapy seems to bear increasing potential for cancer 
treatment. Interestingly, a liposome-based miR-34 mimetic, MRX34, is the first cancer-
targeting miRNA-based drug in Phase I clinical trials in patients with advanced or 
metastatic liver cancer (Ling et al, 2013). In orthotropic hepatocellular carcinoma mouse 
models MRX34 injection into the tail-vein resulted in reduced tumor growth and 
104
increased survival rates (Bader, 2012). This supports the importance of miR-34-
mediated target regulation in the carcinogenesis and may be, at least in part, due to the 
direct inhibition of ZNF281 by miR-34a. However, whether ZNF281 down-regulation is 
necessary for these effects remains to be shown. 
   In summary, ZNF281 was shown to represent an EMT-inducing transcription factor 
and that it presumably participates in the regulation of stemness and pluripotency by 
interaction with the transcription factors NANOG, OCT4, SOX2 and c-MYC in 
untransformed cells. Furthermore, there is evidence that ZNF281 also contributes to 
stemness in tumor stem cells (Figure 57). Nevertheless, the functional and organismal 
analysis of ZNF281 is still in its beginnings and many aspects still require more 
analyses. For example, the functional consequences of the direct interaction between 
the oncoprotein c-MYC and ZNF281 are still unknown (Koch et al, 2007). Potentially, 
ZNF281 could be used as both a disease marker of (c-MYC-driven) tumors and as a 
potential drug target. The identification of small molecules specifically preventing the 
DNA-binding of the ZNF281 transcription factor could also be part of future 
investigations towards cancer therapy. The results described here suggest that ZNF281 
may be an interesting therapeutic target to inhibit metastasis. In the future it will be 
important to further illuminate the role and regulation of ZNF281 in diverse physiological 
and pathological processes in more detail. This knowledge will potentially serve as a 
basis for novel cancer diagnostic and therapeutic approaches in the future. 
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 Figure 57: Model summarizing the regulation and function of ZNF281 presented in this 
thesis and in previous studies. Summary of regulations affecting ZNF281 expression/function 
and processes/factors regulated by ZNF281. Dashed lines indicate connections (protein 
interactions, gene regulations) for which the functional consequences still have to be 
determined. Red arrows symbolize inhibitions and green arrows indicate inductions (Hahn & 
Hermeking, 2014, revised version submitted). 
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7. SUMMARY 
   The vast majority of colorectal cancer (CRC)-related deaths is caused by the 
metastatic spread of tumor cells to distant organs rather than by the growth of the 
primary tumor. However, until today the mechanisms involved in CRC metastasis are 
not completely understood. For cancer cells the epithelial-mesenchymal transition 
(EMT) is thought to represent a prerequisite to invade adjacent tissue and form 
metastases at distant sites. Transcription factors, cytokines or oncogenic signaling 
pathways play an important role in the regulation of the EMT program. Recently, the 
oncoprotein c-MYC was shown to induce EMT, e.g. by enhancing SNAIL expression. 
Previously an interaction between c-MYC and the transcription factor ZNF281/ZBP-99 
has been described. However, so far it remained elusive which upstream signals 
regulate ZNF281 levels or activity and furthermore, what functions are mediated by 
ZNF281, which may contribute to the c-MYC-mediated tumor progression. Here, it could 
be shown that SNAIL and miR-34a/b/c control the expression of ZNF281 in a coherent 
feed-forward-loop: the EMT-transcription factor SNAIL directly induced ZNF281 
transcription and repressed miR-34a/b/c, thereby alleviating ZNF281 from direct down-
regulation by miR-34. Moreover, p53 activation led to a miR-34a-dependent down-
regulation of ZNF281 expression. Additionally, in CRC cells it could be demonstrated, 
that ectopic ZNF281 expression induces EMT. This process was mediated by and 
dependent on the direct induction of SNAIL. Furthermore, ectopic ZNF281 increased 
migration/invasion, and enhanced β-catenin activity. Expression of the stemness 
markers LGR5 was directly and CD133 indirectly induced by ectopic ZNF281 
expression, which also increased sphere formation. Conversely, in CRC cells the 
experimental down-regulation of ZNF281 resulted in a mesenchymal-epithelial transition 
(MET), inhibited migration/invasion and decreased sphere formation. Additionally, 
repression of ZNF281 led to decreased formation of lung metastases by CRC cells in a 
xenograft mouse tumor model. Furthermore, ZNF281 protein expression was indirectly 
elevated by ectopic c-MYC expression. Inactivation of ZNF281 prevented the induction 
of EMT by c-MYC or SNAIL. The analysis of tumor samples revealed that ZNF281 
expression increases during CRC progression and correlates with tumor recurrence.  
   Taken together, the results identify ZNF281 as a new EMT-promoting transcription 
factor, which contributes to metastasis formation in CRC. In the future, this knowledge 
may be exploited for therapeutic and diagnostic purposes in cancer therapy. 
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8. ZUSAMMENFASSUNG 
   Die überwiegende Mehrheit der durch das Kolorektalkarzinom (KRK) bedingten 
Todesfälle wird durch das metastatische Ausbreiten von Tumorzellen in von dem 
Primärtumor entferntere Organe verursacht, anstatt durch das lokale Wachstum des 
Primärtumors. Die für die Metastasierung von KRK verantwortlichen Mechanismen sind 
jedoch bis heute noch nicht vollständig aufgeklärt. Die epithelial-mesenchymale 
Transition (EMT) wird als Voraussetzung dafür angesehen, dass Krebszellen in 
angrenzendes Gewebe und die Blutbahn eindringen und so in entfernten Organen 
Metastasen bilden können. Transkriptionsfaktoren, Zytokine oder onkogen-wirkende 
Signalwege spielen eine wichtige Rolle in der Regulation des EMT-Programmes. Vor 
Kurzem konnte gezeigt werden, dass das c-MYC Onkoprotein, beispielsweise durch die 
Induktion von SNAIL, EMT regulieren kann. Weiterhin konnte zuvor die Interaktion 
zwischen c-MYC und dem Transkriptionsfaktor ZNF281/ZBP-99 beschrieben werden. 
Jedoch war bisher kaum oder nicht bekannt, welche übergeordneten Signale die 
Expression oder Aktivität von ZNF281 regulieren und des Weiteren, welche Funktionen 
durch ZNF281 ausgeübt werden, die zu der c-MYC-vermittelten Tumorprogression 
beitragen können. In dieser Arbeit konnte gezeigt werden, dass die Expression von 
ZNF281 durch SNAIL und miR-34a/b/c in einer kohärent vorwärts-gerichteten 
Regulationsschleife kontrolliert wird: der EMT-hervorrufende Transkriptionsfaktor SNAIL 
induzierte direkt die ZNF281 Transkription und reprimierte miR-34a/b/c, wodurch die 
direkte Repression von ZNF281 durch miR-34 abgeschwächt wird. Darüber hinaus 
resultierte die Aktivierung des Tumorsupressors p53 in der miR-34a-abhängigen 
Unterdrückung der ZNF281 Expression. Außerdem konnte gezeigt werden, dass die 
ektopische ZNF281 Expression in KRK-Zellen EMT induziert. Dieser Prozess wird 
durch die direkte Induktion von SNAIL vermittelt. Zudem erhöhte die ektopische 
Expression von ZNF281 die Migration/Invasion und verstärkte die β-Catenin Aktivität. 
Durch ektopische ZNF281 Expression wurde die Expression der Stammzellmarker 
LGR5 direkt und CD133 indirekt gesteigert. Hierdurch wurde zusätzlich die Fähigkeit 
von KRK-Zellen Sphären zu bilden verstärkt. Im Gegensatz dazu resultierte die 
experimentelle Repression von ZNF281 in KRK-Zellen in einer mesenchymal-
epithelialen Transition (MET), einer verminderten Migration und Invasion sowie einer 
verringerten Zellsphärenbildung. Zusätzlich führte die Verminderung von ZNF281 zu 
einer geringeren Bildung von Lungenmetastasen durch KRK-Zellen in einem Xenograft-
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Maustumormodell. Außerdem konnte die ZNF281 Expression durch ektopisches c-MYC 
gesteigert werden. Die Inaktivierung von ZNF281 verhinderte die Induktion einer EMT 
durch c-MYC oder SNAIL. Die Analyse von Patientenproben ergab, dass die ZNF281 
Expression mit fortschreitendem Verlauf bei KRK ansteigt und mit dem Wiederauftreten 
des Tumors nach Therapie korreliert.  
   Zusammenfassend konnte der Transkriptionsfaktor ZNF281 als ein EMT-fördernder 
Faktor identifiziert werden, welcher zur Bildung von Metastasen bei KRK beiträgt. In der 
Zukunft könnte dieses Wissen für therapeutische und diagnostische Zwecke in der 
Krebstherapie genutzt werden.  
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